Raras
Buscar doenças, sintomas, genes...
Neuropatia periférica, genética
ORPHA:98497DOENÇA RARA
heart

Um caso de neuropatia periférica causada por uma modificação genômica herdada em um indivíduo.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Um caso de neuropatia periférica causada por uma modificação genômica herdada em um indivíduo.

Publicações científicas
7 artigos
Último publicado: 2026 Mar
Medicamentos
18 registrados
PATISIRAN SODIUM, VUTRISIRAN SODIUM, INOTERSEN SODIUM

Tem tratamento?

18 medicamentos registrados
Ver detalhes, fases e interações →
PATISIRAN SODIUMVUTRISIRAN SODIUMINOTERSEN SODIUMVUTRISIRANCHENODIOLRISDIPLAMTORIPALIMABATIDARSAGENE AUTOTEMCELPATISIRANINOTERSEN

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-5 / 10 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
40.0
Worldwide
🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
204 sintomas
💪
Músculos
131 sintomas
🦴
Ossos e articulações
126 sintomas
👁️
Olhos
90 sintomas
😀
Face
68 sintomas
❤️
Coração
59 sintomas

+ 813 sintomas em outras categorias

Características mais comuns

Pé cavo
Deformidades congênitas de contratura do pé
Anormalidade da gengiva
Morfologia anormal do hipocampo
Crepitação da articulação temporomandibular
Bater a cabeça
1792sintomas
Sem dados (1792)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 1792 características clínicas mais associadas, ordenadas por frequência.

Pé cavoPes cavus
Deformidades congênitas de contratura do péCongenital foot contraction deformities
Anormalidade da gengivaAbnormality of the gingiva
Morfologia anormal do hipocampoAbnormal hippocampus morphology
Crepitação da articulação temporomandibularTemporomandibular joint crepitus

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico7PubMed
Últimos 10 anos7publicações
Pico20222 papers
Linha do tempo
2026Hoje · 2026🧪 1986Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

81 genes identificados com associação a esta condição.

Curadoria gene-doença

fontes oficiais
IGHMBP2SARS1SCN9APLEKHG5
IGHMBP2
FHFumarate hydratase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the reversible stereospecific interconversion of fumarate to L-malate (PubMed:30761759). Experiments in other species have demonstrated that specific isoforms of this protein act in defined pathways and favor one direction over the other (Probable) Catalyzes the hydration of fumarate to L-malate in the tricarboxylic acid (TCA) cycle to facilitate a transition step in the production of energy in the form of NADH Catalyzes the dehydration of L-malate to fumarate (By similarity). Fumarate

LOCALIZAÇÃO

MitochondrionCytoplasm, cytosolNucleusChromosome

VIAS BIOLÓGICAS (2)
Citric acid cycle (TCA cycle)Mitochondrial protein degradation
MECANISMO DE DOENÇA

Fumarase deficiency

A severe autosomal recessive metabolic disorder characterized by early-onset hypotonia, profound psychomotor retardation, and brain abnormalities, such as agenesis of the corpus callosum, gyral defects, and ventriculomegaly. Many patients show neonatal distress, metabolic acidosis, and/or encephalopathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
139.4 TPM
Fibroblastos
128.8 TPM
Coração - Ventrículo esquerdo
120.5 TPM
Músculo esquelético
115.0 TPM
Fígado
104.5 TPM
OUTRAS DOENÇAS (3)
fumaric aciduriahereditary leiomyomatosis and renal cell cancerhereditary pheochromocytoma-paraganglioma
HGNC:3700UniProt:P07954
MT-TVCandidate gene tested inDesconhecido
LOCALIZAÇÃO

VIAS BIOLÓGICAS (3)
G alpha (i) signalling eventsFormyl peptide receptors bind formyl peptides and many other ligandsG alpha (q) signalling events
OUTRAS DOENÇAS (2)
mitochondrial diseasematernally-inherited Leigh syndrome
HGNC:7500
MT-ND3NADH-ubiquinone oxidoreductase chain 3Candidate gene tested inDesconhecido
FUNÇÃO

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (PubMed:25118196). Essential for the catalytic activity of complex I (PubMed:25118196)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (3)
Respiratory electron transportComplex I biogenesisMitochondrial translation termination
MECANISMO DE DOENÇA

Leigh syndrome

An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia.

OUTRAS DOENÇAS (4)
mitochondrial diseasematernally-inherited Leigh syndromeLeber plus diseasemitochondrial complex I deficiency
HGNC:7458UniProt:P03897
ARSAATPase GET3Candidate gene tested inTolerante
FUNÇÃO

ATPase required for the post-translational delivery of tail-anchored (TA) proteins to the endoplasmic reticulum (PubMed:17382883). Recognizes and selectively binds the transmembrane domain of TA proteins in the cytosol. This complex then targets to the endoplasmic reticulum by membrane-bound receptors GET1/WRB and CAMLG/GET2, where the tail-anchored protein is released for insertion. This process is regulated by ATP binding and hydrolysis. ATP binding drives the homodimer towards the closed dime

LOCALIZAÇÃO

CytoplasmEndoplasmic reticulumNucleus, nucleolus

VIAS BIOLÓGICAS (2)
The activation of arylsulfatasesGlycosphingolipid catabolism
MECANISMO DE DOENÇA

Cardiomyopathy, dilated, 2H

A form of dilated cardiomyopathy, a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. CMD2H is an autosomal recessive form characterized by rapid progression and death in early infancy.

OUTRAS DOENÇAS (3)
metachromatic leukodystrophy, juvenile formmetachromatic leukodystrophy, late infantile formmetachromatic leukodystrophy, adult form
HGNC:713UniProt:O43681
GANGigaxoninCandidate gene tested inTolerante
FUNÇÃO

Probable cytoskeletal component that directly or indirectly plays an important role in neurofilament architecture. May act as a substrate-specific adapter of an E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Controls degradation of TBCB. Controls degradation of MAP1B and MAP1S, and is critical for neuronal maintenance and survival

LOCALIZAÇÃO

CytoplasmCytoplasm, cytoskeleton

VIAS BIOLÓGICAS (2)
Antigen processing: Ubiquitination & Proteasome degradationNeddylation
MECANISMO DE DOENÇA

Giant axonal neuropathy 1, autosomal recessive

A severe autosomal recessive sensorimotor neuropathy affecting both the peripheral nerves and the central nervous system. Axonal loss and the presence of giant axonal swellings filled with neurofilaments on nerve biopsies are the hallmarks of this neurodegenerative disorder.

EXPRESSÃO TECIDUAL(Ubíquo)
Skin Not Sun Exposed Suprapubic
31.2 TPM
Skin Sun Exposed Lower leg
31.0 TPM
Vagina
8.4 TPM
Esôfago - Mucosa
8.1 TPM
Cérebro - Hemisfério cerebelar
5.8 TPM
OUTRAS DOENÇAS (1)
giant axonal neuropathy 1
HGNC:4137UniProt:Q9H2C0
YARS1Tyrosine--tRNA ligase, cytoplasmicCandidate gene tested inTolerante
FUNÇÃO

Tyrosine--tRNA ligase that catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr-AMP and then transferred to the acceptor end of tRNA(Tyr) (Probable) (PubMed:25533949). Also acts as a positive regulator of poly-ADP-ribosylation in the nucleus, independently of its tyrosine--tRNA ligase activity (PubMed:25533949). Activity is switched upon resveratrol-binding: resveratrol strongly inhibits the tyrosine--tRNA ligase activity and pr

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
Cytosolic tRNA aminoacylation
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, dominant intermediate C

A form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. The dominant intermediate type C is characterized by clinical and pathologic features intermediate between demyelinating and axonal peripheral neuropathies, and motor median nerve conduction velocities ranging from 25 to 45 m/sec.

OUTRAS DOENÇAS (2)
neurologic, endocrine, and pancreatic disease, multisystem, infantile-onset 2Charcot-Marie-Tooth disease dominant intermediate C
HGNC:12840UniProt:P54577
IARS2Isoleucine--tRNA ligase, mitochondrialCandidate gene tested inRestrito
FUNÇÃO

Aminoacyl-tRNA synthetase that catalyzes the specific attachment of isoleucine to its cognate tRNA (tRNA(Ile))

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (2)
Mitochondrial protein degradationMitochondrial tRNA aminoacylation
MECANISMO DE DOENÇA

Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia

An autosomal recessive disorder characterized by cataracts, short-stature secondary to growth hormone deficiency, sensorineural hearing deficit, peripheral sensory neuropathy, skeletal dysplasia, scoliosis, and facial dysmorphism.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
107.8 TPM
Linfócitos
84.2 TPM
Glândula adrenal
72.5 TPM
Artéria tibial
71.5 TPM
Tecido adiposo
69.7 TPM
OUTRAS DOENÇAS (2)
cataract-growth hormone deficiency-sensory neuropathy-sensorineural hearing loss-skeletal dysplasia syndromeLeigh syndrome
HGNC:29685UniProt:Q9NSE4
HARS1Histidine--tRNA ligase, cytoplasmicCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the ATP-dependent ligation of histidine to the 3'-end of its cognate tRNA, via the formation of an aminoacyl-adenylate intermediate (His-AMP) (PubMed:29235198). Plays a role in axon guidance (PubMed:26072516)

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Cytosolic tRNA aminoacylation
MECANISMO DE DOENÇA

Usher syndrome 3B

A syndrome characterized by progressive vision and hearing loss during early childhood. Some patients have the so-called 'Charles Bonnet syndrome,' involving decreased visual acuity and vivid visual hallucinations. USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH3 is characterized by postlingual, progressive hearing loss, variable vestibular dysfunction, and onset of retinitis pigmentosa symptoms, including nyctalopia, constriction of the visual fields, and loss of central visual acuity, usually by the second decade of life.

OUTRAS DOENÇAS (3)
Usher syndrome type 3Bautosomal dominant Charcot-Marie-Tooth disease type 2WUsher syndrome type 3
HGNC:4816UniProt:P12081
DYNC1H1Cytoplasmic dynein 1 heavy chain 1Candidate gene tested inAltamente restrito
FUNÇÃO

Cytoplasmic dynein 1 acts as a motor for the intracellular retrograde motility of vesicles and organelles along microtubules. Dynein has ATPase activity; the force-producing power stroke is thought to occur on release of ADP. Plays a role in mitotic spindle assembly and metaphase plate congression (PubMed:27462074)

LOCALIZAÇÃO

Cytoplasm, cytoskeleton

VIAS BIOLÓGICAS (10)
AggrephagyAmplification of signal from unattached kinetochores via a MAD2 inhibitory signalRHO GTPases Activate ForminsMitotic PrometaphaseEML4 and NUDC in mitotic spindle formation
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2O

An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
147.9 TPM
Cérebro - Hemisfério cerebelar
140.0 TPM
Cerebelo
129.1 TPM
Nervo tibial
80.3 TPM
Artéria tibial
78.4 TPM
OUTRAS DOENÇAS (4)
autosomal dominant childhood-onset proximal spinal muscular atrophy without contracturesCharcot-Marie-Tooth disease axonal type 2Ointellectual disability, autosomal dominant 13autosomal dominant non-syndromic intellectual disability
HGNC:2961UniProt:Q14204
RRM2BRibonucleoside-diphosphate reductase subunit M2 BCandidate gene tested inTolerante
FUNÇÃO

Plays a pivotal role in cell survival by repairing damaged DNA in a p53/TP53-dependent manner. Supplies deoxyribonucleotides for DNA repair in cells arrested at G1 or G2. Contains an iron-tyrosyl free radical center required for catalysis. Forms an active ribonucleotide reductase (RNR) complex with RRM1 which is expressed both in resting and proliferating cells in response to DNA damage

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (2)
TP53 Regulates Metabolic GenesInterconversion of nucleotide di- and triphosphates
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 8A

A disorder due to mitochondrial dysfunction characterized by various combinations of neonatal hypotonia, neurological deterioration, respiratory distress, lactic acidosis, and renal tubulopathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
35.2 TPM
Tireoide
33.1 TPM
Fibroblastos
25.4 TPM
Aorta
22.0 TPM
Pulmão
20.7 TPM
OUTRAS DOENÇAS (7)
progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 5rod-cone dystrophy, sensorineural deafness, and Fanconi-type renal dysfunctionmitochondrial DNA depletion syndrome 8aKearns-Sayre syndrome
HGNC:17296UniProt:Q7LG56
COQ4Ubiquinone biosynthesis protein COQ4 homolog, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Lyase that catalyzes the C1-decarboxylation of 4-hydroxy-3-methoxy-5-(all-trans-decaprenyl)benzoic acid into 2-methoxy-6-(all-trans-decaprenyl)phenol during ubiquinone biosynthesis

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Ubiquinol biosynthesis
MECANISMO DE DOENÇA

Coenzyme Q10 deficiency, primary, 7

An autosomal recessive disorder resulting from mitochondrial dysfunction and characterized by decreased levels of coenzyme Q10, and severe cardiac or neurologic symptoms soon after birth, usually resulting in death. Rarely, symptoms may have later onset.

VIAS REACTOME (1)
OUTRAS DOENÇAS (2)
spastic ataxia 10, autosomal recessiveneonatal encephalomyopathy-cardiomyopathy-respiratory distress syndrome
HGNC:19693UniProt:Q9Y3A0
GDAP1Ganglioside-induced differentiation-associated protein 1Candidate gene tested inTolerante
FUNÇÃO

Regulates the mitochondrial network by promoting mitochondrial fission

LOCALIZAÇÃO

Mitochondrion outer membraneCytoplasm

VIAS BIOLÓGICAS (1)
Class I peroxisomal membrane protein import
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, demyelinating, type 4A

A recessive demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet. By convention autosomal recessive forms of demyelinating Charcot-Marie-Tooth disease are designated CMT4. CMT4A is a severe form characterized by early age of onset and rapid progression leading to inability to walk in late childhood or adolescence.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
80.1 TPM
Brain Frontal Cortex BA9
56.7 TPM
Cerebelo
56.0 TPM
Pituitária
40.1 TPM
Brain Anterior cingulate cortex BA24
37.6 TPM
OUTRAS DOENÇAS (6)
Charcot-Marie-Tooth disease type 4ACharcot-Marie-Tooth disease, axonal, with vocal cord paresis, autosomal recessiveCharcot-Marie-Tooth disease recessive intermediate ACharcot-Marie-Tooth disease axonal type 2K
HGNC:15968UniProt:Q8TB36
MARS1Methionine--tRNA ligase, cytoplasmicCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the specific attachment of an amino acid to its cognate tRNA in a 2 step reaction: the amino acid (AA) is first activated by ATP to form AA-AMP and then transferred to the acceptor end of the tRNA (PubMed:11714285). Plays a role in the synthesis of ribosomal RNA in the nucleolus (PubMed:10791971)

LOCALIZAÇÃO

Cytoplasm, cytosolNucleus, nucleolus

VIAS BIOLÓGICAS (3)
Selenoamino acid metabolismCytosolic tRNA aminoacylationTranscriptional and post-translational regulation of MITF-M expression and activity
MECANISMO DE DOENÇA

Interstitial lung and liver disease

An autosomal recessive, life-threatening disorder characterized by respiratory insufficiency and progressive liver disease with onset in infancy or early childhood. Clinical features include failure to thrive, hypotonia, intermittent lactic acidosis, aminoaciduria, hypothyroidism, interstitial lung disease, pulmonary alveolar proteinosis, anemia, and liver canalicular cholestasis, steatosis, and iron deposition.

OUTRAS DOENÇAS (4)
severe early-onset pulmonary alveolar proteinosis due to MARS deficiencyautosomal recessive spastic paraplegia type 70Charcot-Marie-Tooth disease axonal type 2Utrichothiodystrophy 9, nonphotosensitive
HGNC:6898UniProt:P56192
FDXRNADPH:adrenodoxin oxidoreductase, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Serves as the first electron transfer protein in all the mitochondrial P450 systems including cholesterol side chain cleavage in all steroidogenic tissues, steroid 11-beta hydroxylation in the adrenal cortex, 25-OH-vitamin D3-24 hydroxylation in the kidney, and sterol C-27 hydroxylation in the liver (By similarity). Also acts as a ferredoxin--NADP(+) reductase essential for coenzyme Q biosynthesis: together with FDX2, transfers the electrons required for the hydroxylation reaction performed by C

LOCALIZAÇÃO

MitochondrionMitochondrion inner membrane

VIAS BIOLÓGICAS (4)
Electron transport from NADPH to FerredoxinEndogenous sterolsPregnenolone biosynthesisDefective CYP11A1 causes AICSR
MECANISMO DE DOENÇA

Auditory neuropathy and optic atrophy

An autosomal recessive disease characterized by hearing loss, visual impairment and optic atrophy, with onset in the first or second decades of life. Optic atrophy is caused by degeneration of nerve fibers which arise in the retina and converge to form the optic disk, optic nerve, optic chiasm and optic tracts.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
302.8 TPM
Testículo
77.8 TPM
Baço
43.0 TPM
Linfócitos
37.8 TPM
Ovário
37.6 TPM
OUTRAS DOENÇAS (3)
multiple mitochondrial dysfunctions syndrome 9bauditory neuropathy-optic atrophy syndromeoptic atrophy-ataxia-peripheral neuropathy-global developmental delay syndrome
HGNC:3642UniProt:P22570
PEX11BPeroxisomal membrane protein 11BCandidate gene tested inTolerante
FUNÇÃO

Involved in peroxisomal proliferation (PubMed:9792670). May regulate peroxisome division by recruiting the dynamin-related GTPase DNM1L to the peroxisomal membrane (PubMed:12618434). Promotes membrane protrusion and elongation on the peroxisomal surface (PubMed:20826455)

LOCALIZAÇÃO

Peroxisome membrane

VIAS BIOLÓGICAS (1)
Class I peroxisomal membrane protein import
MECANISMO DE DOENÇA

Peroxisome biogenesis disorder 14B

An autosomal recessive peroxisome biogenesis disorder characterized clinically by mild intellectual disability, congenital cataracts, progressive hearing loss, and polyneuropathy. Additionally, recurrent migraine-like episodes following mental stress or physical exertion, not a common feature in peroxisome disorders, are observed.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Frontal Cortex BA9
64.0 TPM
Cérebro - Hemisfério cerebelar
63.3 TPM
Linfócitos
57.4 TPM
Testículo
54.2 TPM
Cerebelo
51.1 TPM
OUTRAS DOENÇAS (3)
peroxisome biogenesis disorder 14Bobsolete neonatal adrenoleukodystrophyZellweger spectrum disorders
HGNC:8853UniProt:O96011
PEX19Peroxisomal biogenesis factor 19Candidate gene tested inTolerante
FUNÇÃO

Necessary for early peroxisomal biogenesis. Acts both as a cytosolic chaperone and as an import receptor for peroxisomal membrane proteins (PMPs). Binds and stabilizes newly synthesized PMPs in the cytoplasm by interacting with their hydrophobic membrane-spanning domains, and targets them to the peroxisome membrane by binding to the integral membrane protein PEX3. Excludes CDKN2A from the nucleus and prevents its interaction with MDM2, which results in active degradation of TP53

LOCALIZAÇÃO

CytoplasmPeroxisome membrane

VIAS BIOLÓGICAS (3)
ABC transporters in lipid homeostasisDengue Virus-Host InteractionsClass I peroxisomal membrane protein import
MECANISMO DE DOENÇA

Peroxisome biogenesis disorder complementation group 14

A peroxisomal disorder arising from a failure of protein import into the peroxisomal membrane or matrix. The peroxisome biogenesis disorders (PBD group) are genetically heterogeneous with at least 14 distinct genetic groups as concluded from complementation studies. Include disorders are: Zellweger syndrome (ZWS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and classical rhizomelic chondrodysplasia punctata (RCDP). ZWS, NALD and IRD are distinct from RCDP and constitute a clinical continuum of overlapping phenotypes known as the Zellweger spectrum (PBD-ZSS).

EXPRESSÃO TECIDUAL(Ubíquo)
Tecido adiposo
67.4 TPM
Adipose Visceral Omentum
60.0 TPM
Mama
57.5 TPM
Ovário
56.4 TPM
Artéria tibial
55.3 TPM
OUTRAS DOENÇAS (3)
peroxisome biogenesis disorder 12A (Zellweger)Zellweger spectrum disordersobsolete neonatal adrenoleukodystrophy
HGNC:9713UniProt:P40855
MPZMyelin protein P0Candidate gene tested inTolerante
FUNÇÃO

Is an adhesion molecule necessary for normal myelination in the peripheral nervous system. It mediates adhesion between adjacent myelin wraps and ultimately drives myelin compaction

LOCALIZAÇÃO

Cell membraneMyelin membrane

VIAS BIOLÓGICAS (1)
EGR2 and SOX10-mediated initiation of Schwann cell myelination
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, demyelinating, type 1B

A dominant demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
5300.7 TPM
Cólon sigmoide
34.0 TPM
Esôfago - Junção
31.7 TPM
Esôfago - Muscular
30.5 TPM
Artéria coronária
19.6 TPM
OUTRAS DOENÇAS (9)
Roussy-Levy syndromeneuropathy, congenital hypomyelinating, 2Charcot-Marie-Tooth disease dominant intermediate DCharcot-Marie-Tooth disease type 2I
HGNC:7225UniProt:P25189
MFN2Mitofusin-2Candidate gene tested inTolerante
FUNÇÃO

Mitochondrial outer membrane GTPase that mediates mitochondrial clustering and fusion (PubMed:11181170, PubMed:11950885, PubMed:19889647, PubMed:26214738, PubMed:28114303). Mitochondria are highly dynamic organelles, and their morphology is determined by the equilibrium between mitochondrial fusion and fission events (PubMed:28114303). Overexpression induces the formation of mitochondrial networks (PubMed:28114303). Membrane clustering requires GTPase activity and may involve a major rearrangeme

LOCALIZAÇÃO

Mitochondrion outer membrane

VIAS BIOLÓGICAS (2)
Factors involved in megakaryocyte development and platelet productionRHOT2 GTPase cycle
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2A2B

An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. CMT2A2B is a severe form with autosomal recessive inheritance.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
173.4 TPM
Músculo esquelético
158.4 TPM
Esôfago - Muscular
143.1 TPM
Coração - Átrio
137.5 TPM
Esôfago - Junção
119.7 TPM
OUTRAS DOENÇAS (7)
multiple symmetric lipomatosisCharcot-Marie-Tooth disease type 2A2Charcot-Marie-Tooth disease, axonal, autosomal recessive, type 2a2b;neuropathy, hereditary motor and sensory, type 6A
HGNC:16877UniProt:O95140
GSNGelsolinCandidate gene tested inTolerante
FUNÇÃO

Calcium-regulated, actin-modulating protein that binds to the plus (or barbed) ends of actin monomers or filaments, preventing monomer exchange (end-blocking or capping). It can promote the assembly of monomers into filaments (nucleation) as well as sever filaments already formed (PubMed:19666512). Plays a role in ciliogenesis (PubMed:20393563)

LOCALIZAÇÃO

Cytoplasm, cytoskeletonSecreted

MECANISMO DE DOENÇA

Amyloidosis, hereditary systemic 4, Finnish type

A form of hereditary systemic amyloidosis, a disorder characterized by amyloid deposition in multiple tissues resulting in a wide clinical spectrum. AMYLD4 is due to gelsolin amyloid deposition and is typically characterized by cranial neuropathy and lattice corneal dystrophy. Most patients have modest involvement of internal organs, but severe systemic disease can develop in some individuals causing peripheral polyneuropathy, amyloid cardiomyopathy, and nephrotic syndrome leading to renal failure. AMYLD4 is usually inherited in an autosomal dominant pattern. However, homozygotes with a more severe phenotype have also been reported.

EXPRESSÃO TECIDUAL(Ubíquo)
Tecido adiposo
2343.5 TPM
Nervo tibial
1919.4 TPM
Artéria tibial
1624.6 TPM
Aorta
1619.7 TPM
Artéria coronária
1564.3 TPM
OUTRAS DOENÇAS (1)
Finnish type amyloidosis
HGNC:4620UniProt:P06396
AARS1Alanine--tRNA ligase, cytoplasmicCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the attachment of alanine to tRNA(Ala) in a two-step reaction: alanine is first activated by ATP to form Ala-AMP and then transferred to the acceptor end of tRNA(Ala) (PubMed:27622773, PubMed:27911835, PubMed:28493438, PubMed:33909043). Also edits incorrectly charged tRNA(Ala) via its editing domain (PubMed:27622773, PubMed:27911835, PubMed:28493438, PubMed:29273753). In presence of high levels of lactate, also acts as a protein lactyltransferase that mediates lactylation of lysine res

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
Cytosolic tRNA aminoacylation
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2N

An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.

OUTRAS DOENÇAS (6)
trichothiodystrophy 8, nonphotosensitiveleukoencephalopathy, hereditary diffuse, with spheroids 2developmental and epileptic encephalopathy, 29Charcot-Marie-Tooth disease axonal type 2N
HGNC:20UniProt:P49588
SPTLC2Serine palmitoyltransferase 2Candidate gene tested inAltamente restrito
FUNÇÃO

Component of the serine palmitoyltransferase multisubunit enzyme (SPT) that catalyzes the initial and rate-limiting step in sphingolipid biosynthesis by condensing L-serine and activated acyl-CoA (most commonly palmitoyl-CoA) to form long-chain bases (PubMed:19416851, PubMed:19648650, PubMed:20504773, PubMed:20920666). The SPT complex is composed of SPTLC1, SPTLC2 or SPTLC3 and SPTSSA or SPTSSB. Within this complex, the heterodimer consisting of SPTLC1 and SPTLC2/SPTLC3 forms the catalytic core

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Sphingolipid de novo biosynthesis
MECANISMO DE DOENÇA

Neuropathy, hereditary sensory and autonomic, 1C

A form of hereditary sensory and autonomic neuropathy, a genetically and clinically heterogeneous group of disorders characterized by degeneration of dorsal root and autonomic ganglion cells, and by prominent sensory abnormalities with a variable degree of motor and autonomic dysfunction. The neurological phenotype is often complicated by severe infections, osteomyelitis, and amputations. HSAN1C symptoms include loss of touch and vibration in the feet, dysesthesia and severe panmodal sensory loss in the upper and lower limbs, distal lower limb sensory loss with ulceration and osteomyelitis, and distal muscle weakness.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
49.9 TPM
Baço
29.7 TPM
Esôfago - Mucosa
26.9 TPM
Adipose Visceral Omentum
25.0 TPM
Tecido adiposo
24.1 TPM
OUTRAS DOENÇAS (2)
neuropathy, hereditary sensory and autonomic, type 1Chereditary sensory and autonomic neuropathy type 1
HGNC:11278UniProt:O15270
NEFLNeurofilament light polypeptideCandidate gene tested inTolerante
FUNÇÃO

Neurofilaments usually contain three intermediate filament proteins: NEFL, NEFM, and NEFH which are involved in the maintenance of neuronal caliber. May additionally cooperate with the neuronal intermediate filament proteins PRPH and INA to form neuronal filamentous networks (By similarity)

LOCALIZAÇÃO

Cell projection, axonCytoplasm, cytoskeleton

VIAS BIOLÓGICAS (6)
RAF/MAP kinase cascadeRas activation upon Ca2+ influx through NMDA receptorUnblocking of NMDA receptors, glutamate binding and activationLong-term potentiationNegative regulation of NMDA receptor-mediated neuronal transmission
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, demyelinating, type 1F

A dominant demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet. CMT1F is characterized by onset in infancy or childhood (range 1 to 13 years).

EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Frontal Cortex BA9
487.2 TPM
Córtex cerebral
328.6 TPM
Brain Anterior cingulate cortex BA24
195.3 TPM
Hipotálamo
136.9 TPM
Substância negra
100.6 TPM
OUTRAS DOENÇAS (4)
Charcot-Marie-Tooth disease type 1FCharcot-Marie-Tooth disease, dominant intermediate GCharcot-Marie-Tooth disease type 2ECharcot-Marie-Tooth disease type 2B5
HGNC:7739UniProt:P07196
SMN2Survival motor neuron proteinCandidate gene tested inModerado
FUNÇÃO

The SMN complex catalyzes the assembly of small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome, and thereby plays an important role in the splicing of cellular pre-mRNAs (PubMed:18984161, PubMed:9845364). Most spliceosomal snRNPs contain a common set of Sm proteins SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE, SNRPF and SNRPG that assemble in a heptameric protein ring on the Sm site of the small nuclear RNA to form the core snRNP (Sm core) (PubMed:18984161). In the cytosol,

LOCALIZAÇÃO

Nucleus, gemNucleus, Cajal bodyCytoplasmCytoplasmic granulePerikaryonCell projection, neuron projectionCell projection, axonCytoplasm, myofibril, sarcomere, Z line

VIAS BIOLÓGICAS (2)
snRNP AssemblySARS-CoV-2 modulates host translation machinery
MECANISMO DE DOENÇA

Spinal muscular atrophy 1

A form of spinal muscular atrophy, a group of neuromuscular disorder characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. Autosomal recessive forms are classified according to the age of onset, the maximum muscular activity achieved, and survivorship. The severity of the disease is mainly determined by the copy number of SMN2, a copy gene which predominantly produces exon 7-skipped transcripts and only low amount of full-length transcripts that encode for a protein identical to SMN1. Only about 4% of SMA patients bear one SMN1 copy with an intragenic mutation. SMA1 is a severe form, with onset before 6 months of age. SMA1 patients never achieve the ability to sit.

EXPRESSÃO TECIDUAL(Baixa expressão)
Cervix Ectocervix
4.9 TPM
Ovário
4.9 TPM
Testículo
4.5 TPM
Útero
4.4 TPM
Linfócitos
4.2 TPM
OUTRAS DOENÇAS (4)
spinal muscular atrophy, type IVspinal muscular atrophy, type 1spinal muscular atrophy, type IIspinal muscular atrophy, type III
HGNC:11118UniProt:Q16637
MTTPMicrosomal triglyceride transfer protein large subunitCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the transport of triglyceride, cholesteryl ester, and phospholipid between phospholipid surfaces (PubMed:15897609, PubMed:16478722, PubMed:22236406, PubMed:23475612, PubMed:25108285, PubMed:26224785, PubMed:8876250, PubMed:8939939). Required for the assembly and secretion of plasma lipoproteins that contain apolipoprotein B (PubMed:16478722, PubMed:23475612, PubMed:26224785, PubMed:8876250, PubMed:8939939). May be involved in regulating cholesteryl ester biosynthesis in cells that prod

LOCALIZAÇÃO

Endoplasmic reticulumGolgi apparatus

VIAS BIOLÓGICAS (3)
VLDL assemblyChylomicron assemblyLDL remodeling
MECANISMO DE DOENÇA

Abetalipoproteinemia

An autosomal recessive disorder of lipoprotein metabolism. Affected individuals produce virtually no circulating apolipoprotein B-containing lipoproteins (chylomicrons, VLDL, LDL, lipoprotein(A)). Malabsorption of the antioxidant vitamin E occurs, leading to spinocerebellar and retinal degeneration.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
31.1 TPM
Intestino delgado
24.7 TPM
Testículo
7.1 TPM
Ovário
1.8 TPM
Linfócitos
1.2 TPM
OUTRAS DOENÇAS (1)
abetalipoproteinemia
HGNC:7467UniProt:P55157
PDHBPyruvate dehydrogenase E1 component subunit beta, mitochondrialCandidate gene tested inRestrito
FUNÇÃO

Together with PDHA1 forms the heterotetrameric E1 subunit of the pyruvate dehydrogenase (PDH) complex (PubMed:17474719, PubMed:19081061). The PDH complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2), and thereby links cytoplasmic glycolysis and the mitochondrial tricarboxylic acid (TCA) cycle (Probable). It contains multiple copies of three enzymatic components: pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and dihydrolipoamide dehydrogenase (E3) (P

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (4)
Signaling by Retinoic AcidRegulation of pyruvate dehydrogenase (PDH) complexPDH complex synthesizes acetyl-CoA from PYRMitochondrial protein degradation
MECANISMO DE DOENÇA

Pyruvate dehydrogenase E1-beta deficiency

An enzymatic defect causing primary lactic acidosis in children. It is associated with a broad clinical spectrum ranging from fatal lactic acidosis in the newborn to chronic neurologic dysfunction with structural abnormalities in the central nervous system without systemic acidosis.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
122.9 TPM
Esôfago - Muscular
118.3 TPM
Fibroblastos
115.0 TPM
Coração - Ventrículo esquerdo
110.6 TPM
Artéria tibial
106.5 TPM
OUTRAS DOENÇAS (1)
pyruvate dehydrogenase E1-beta deficiency
HGNC:8808UniProt:P11177
PDP1Polyisoprenoid diphosphate/phosphate phosphohydrolase PLPP6Candidate gene tested inRestrito
FUNÇÃO

Magnesium-independent polyisoprenoid diphosphatase that catalyzes the sequential dephosphorylation of presqualene, farnesyl, geranyl and geranylgeranyl diphosphates (PubMed:16464866, PubMed:19220020, PubMed:20110354). Functions in the innate immune response through the dephosphorylation of presqualene diphosphate which acts as a potent inhibitor of the signaling pathways contributing to polymorphonuclear neutrophils activation (PubMed:16464866, PubMed:23568778). May regulate the biosynthesis of

LOCALIZAÇÃO

Endoplasmic reticulum membraneNucleus envelopeNucleus inner membrane

VIAS BIOLÓGICAS (1)
Regulation of pyruvate dehydrogenase (PDH) complex
VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Brain Frontal Cortex BA9
51.5 TPM
Glândula adrenal
34.6 TPM
Testículo
29.8 TPM
Córtex cerebral
28.2 TPM
Fibroblastos
20.0 TPM
OUTRAS DOENÇAS (1)
pyruvate dehydrogenase phosphatase deficiency
HGNC:9279UniProt:Q8IY26
DLATDihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

The pyruvate dehydrogenase (PDH) complex, catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2), and thereby links cytoplasmic glycolysis and the mitochondrial tricarboxylic acid (TCA) cycle (Probable). It contains multiple copies of three enzymatic components: pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and dihydrolipoamide dehydrogenase (E3); (Probable). Within this complex, the catalytic function of this enzyme is to accept, and to transfer to coenzyme

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (3)
PDH complex synthesizes acetyl-CoA from PYRProtein lipoylationRegulation of pyruvate dehydrogenase (PDH) complex
EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
38.4 TPM
Linfócitos
37.6 TPM
Coração - Ventrículo esquerdo
36.5 TPM
Fibroblastos
31.1 TPM
Coração - Átrio
26.7 TPM
OUTRAS DOENÇAS (1)
pyruvate dehydrogenase E2 deficiency
HGNC:2896UniProt:P10515
NAIPBaculoviral IAP repeat-containing protein 1Candidate gene tested inTolerante
FUNÇÃO

Anti-apoptotic protein which acts by inhibiting the activities of CASP3, CASP7 and CASP9. Can inhibit the autocleavage of pro-CASP9 and cleavage of pro-CASP3 by CASP9. Capable of inhibiting CASP9 autoproteolysis at 'Asp-315' and decreasing the rate of auto proteolysis at 'Asp-330'. Acts as a mediator of neuronal survival in pathological conditions. Prevents motor-neuron apoptosis induced by a variety of signals. Possible role in the prevention of spinal muscular atrophy that seems to be caused b

LOCALIZAÇÃO

EXPRESSÃO TECIDUAL(Tecido-específico)
Sangue
5.8 TPM
Baço
3.8 TPM
Pulmão
1.3 TPM
Testículo
1.0 TPM
Fallopian Tube
0.9 TPM
OUTRAS DOENÇAS (3)
spinal muscular atrophy, type 1spinal muscular atrophy, type IIspinal muscular atrophy, type III
HGNC:7634UniProt:Q13075
PNKPBifunctional polynucleotide phosphatase/kinaseCandidate gene tested inTolerante
FUNÇÃO

Plays a key role in the repair of DNA damage, functioning as part of both the non-homologous end-joining (NHEJ) and base excision repair (BER) pathways (PubMed:10446192, PubMed:10446193, PubMed:15385968, PubMed:20852255, PubMed:28453785). Through its two catalytic activities, PNK ensures that DNA termini are compatible with extension and ligation by either removing 3'-phosphates from, or by phosphorylating 5'-hydroxyl groups on, the ribose sugar of the DNA backbone (PubMed:10446192, PubMed:10446

LOCALIZAÇÃO

NucleusChromosome

VIAS BIOLÓGICAS (1)
APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway
MECANISMO DE DOENÇA

Microcephaly, seizures, and developmental delay

An autosomal recessive neurodevelopmental disorder characterized by infantile-onset seizures, microcephaly, severe intellectual disability and delayed motor milestones with absent speech or only achieving a few words. Most patients also have behavioral problems with hyperactivity. Microcephaly is progressive and without neuronal migration or structural abnormalities, consistent with primary microcephaly.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
66.8 TPM
Tireoide
63.9 TPM
Baço
59.2 TPM
Glândula adrenal
55.9 TPM
Cervix Endocervix
51.8 TPM
OUTRAS DOENÇAS (4)
microcephaly, seizures, and developmental delayataxia - oculomotor apraxia type 4Charcot-Marie-Tooth disease type 2B2early-infantile DEE
HGNC:9154UniProt:Q96T60
OATOrnithine aminotransferase, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the reversible interconversion of L-ornithine and 2-oxoglutarate to L-glutamate semialdehyde and L-glutamate

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (1)
Glutamate and glutamine metabolism
MECANISMO DE DOENÇA

Hyperornithinemia with gyrate atrophy of choroid and retina

A disorder clinically characterized by a triad of progressive chorioretinal degeneration, early cataract formation, and type II muscle fiber atrophy. Characteristic chorioretinal atrophy with progressive constriction of the visual fields leads to blindness at the latest during the sixth decade of life. Patients generally have normal intelligence.

EXPRESSÃO TECIDUAL(Ubíquo)
Intestino delgado
165.3 TPM
Fibroblastos
139.5 TPM
Aorta
118.9 TPM
Artéria tibial
116.9 TPM
Cervix Endocervix
110.6 TPM
OUTRAS DOENÇAS (1)
ornithine aminotransferase deficiency
HGNC:8091UniProt:P04181
MT-ATP6ATP synthase F(0) complex subunit aCandidate gene tested inDesconhecido
FUNÇÃO

Subunit a, of the mitochondrial membrane ATP synthase complex (F(1)F(0) ATP synthase or Complex V) that produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain (Probable). ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256). These two domains are linked by a central stalk rotating inside the F(1

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (4)
Mitochondrial translation terminationFormation of ATP by chemiosmotic couplingCristae formationMitochondrial protein degradation
MECANISMO DE DOENÇA

Neuropathy, ataxia, and retinitis pigmentosa

A syndrome characterized by variable combination of developmental delay, psychomotor retardation, hearing loss, optic atrophy and retinitis pigmentosa, dementia, seizures, ataxia, proximal neurogenic muscle weakness, and sensory neuropathy.

OUTRAS DOENÇAS (8)
mitochondrial diseasematernally-inherited Leigh syndromefamilial infantile bilateral striatal necrosismitochondrial proton-transporting ATP synthase complex deficiency
HGNC:7414UniProt:P00846
MT-TL1Candidate gene tested inDesconhecido
LOCALIZAÇÃO

VIAS BIOLÓGICAS (3)
G alpha (i) signalling eventsFormyl peptide receptors bind formyl peptides and many other ligandsG alpha (q) signalling events
OUTRAS DOENÇAS (7)
mitochondrial diseasematernally-inherited Leigh syndromeMELAS syndromeMERRF syndrome
HGNC:7490
MT-ND4NADH-ubiquinone oxidoreductase chain 4Candidate gene tested inDesconhecido
FUNÇÃO

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (PubMed:15250827, PubMed:8344246, PubMed:8644732). Essential for the catalytic activity and assembly of complex I (PubMed:15250827, PubMed:8344246, PubMed:8644732)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (3)
Respiratory electron transportComplex I biogenesisMitochondrial translation termination
MECANISMO DE DOENÇA

Leber hereditary optic neuropathy

A maternally inherited form of Leber hereditary optic neuropathy, a mitochondrial disease resulting in bilateral painless loss of central vision due to selective degeneration of the retinal ganglion cells and their axons. The disorder shows incomplete penetrance and male predominance. Cardiac conduction defects and neurological defects have also been described in some LHON patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes.

OUTRAS DOENÇAS (6)
mitochondrial diseasematernally-inherited Leigh syndromeMELAS syndromeLeber plus disease
HGNC:7459UniProt:P03905
ATP1A1Sodium/potassium-transporting ATPase subunit alpha-1Candidate gene tested inAltamente restrito
FUNÇÃO

This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients (PubMed:29499166, PubMed:30388404). Could also be part of an osmosensory signaling pathway that senses body-fluid sodium levels and controls salt intake behavior as well as voluntary

LOCALIZAÇÃO

Cell membraneBasolateral cell membraneCell membrane, sarcolemmaCell projection, axonMelanosome

VIAS BIOLÓGICAS (3)
Ion homeostasisIon transport by P-type ATPasesPotential therapeutics for SARS
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2DD

A dominant axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.

OUTRAS DOENÇAS (2)
Charcot-Marie-tooth disease, axonal, type 2DDhypomagnesemia, seizures, and intellectual disability 2
HGNC:799UniProt:P05023
DGAT2Diacylglycerol O-acyltransferase 2Candidate gene tested inTolerante
FUNÇÃO

Essential acyltransferase that catalyzes the terminal and only committed step in triacylglycerol synthesis by using diacylglycerol and fatty acyl CoA as substrates. Required for synthesis and storage of intracellular triglycerides (PubMed:27184406). Probably plays a central role in cytosolic lipid accumulation. In liver, is primarily responsible for incorporating endogenously synthesized fatty acids into triglycerides (By similarity). Also functions as an acyl-CoA retinol acyltransferase (ARAT)

LOCALIZAÇÃO

Endoplasmic reticulum membraneLipid dropletCytoplasm, perinuclear region

VIAS BIOLÓGICAS (3)
Acyl chain remodeling of DAG and TAGMLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosisTriglyceride biosynthesis
EXPRESSÃO TECIDUAL(Ubíquo)
Skin Sun Exposed Lower leg
195.8 TPM
Skin Not Sun Exposed Suprapubic
161.5 TPM
Adipose Visceral Omentum
126.7 TPM
Sangue
111.6 TPM
Tecido adiposo
108.9 TPM
OUTRAS DOENÇAS (1)
autosomal dominant charcot-marie-tooth disease type 2 due to DGAT2 mutation
HGNC:16940UniProt:Q96PD7
EGR2E3 SUMO-protein ligase EGR2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Sequence-specific DNA-binding transcription factor (PubMed:17717711). Plays a role in hindbrain segmentation by regulating the expression of a subset of homeobox containing genes and in Schwann cell myelination by regulating the expression of genes involved in the formation and maintenance of myelin (By similarity). Binds to two EGR2-consensus sites EGR2A (5'-CTGTAGGAG-3') and EGR2B (5'-ATGTAGGTG-3') in the HOXB3 enhancer and promotes HOXB3 transcriptional activation (By similarity). Binds to sp

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (4)
Activation of anterior HOX genes in hindbrain development during early embryogenesisTranscriptional regulation of white adipocyte differentiationNGF-stimulated transcriptionEGR2 and SOX10-mediated initiation of Schwann cell myelination
MECANISMO DE DOENÇA

Neuropathy, congenital hypomyelinating, 1, autosomal recessive

A severe degenerating neuropathy that results from a congenital impairment in myelin formation. It is clinically characterized by early onset of hypotonia, areflexia, distal muscle weakness, and very slow nerve conduction velocities (as low as 3m/s). Some patients manifest nearly complete absence of spontaneous limb movements, respiratory distress at birth, and complete absence of myelin shown by electron microscopy of peripheral nerves.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
62.6 TPM
Linfócitos
32.8 TPM
Skin Not Sun Exposed Suprapubic
16.8 TPM
Skin Sun Exposed Lower leg
11.0 TPM
Pulmão
7.8 TPM
OUTRAS DOENÇAS (3)
Charcot-Marie-Tooth disease type 4ECharcot-Marie-Tooth disease type 1DCharcot-Marie-Tooth disease type 3
HGNC:3239UniProt:P11161
HADHATrifunctional enzyme subunit alpha, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial trifunctional enzyme catalyzes the last three of the four reactions of the mitochondrial beta-oxidation pathway (PubMed:1550553, PubMed:29915090, PubMed:30850536, PubMed:8135828, PubMed:31604922). The mitochondrial beta-oxidation pathway is the major energy-producing process in tissues and is performed through four consecutive reactions breaking down fatty acids into acetyl-CoA (PubMed:29915090). Among the enzymes involved in this pathway, the trifunctional enzyme exhibits specific

LOCALIZAÇÃO

MitochondrionMitochondrion inner membrane

VIAS BIOLÓGICAS (8)
Acyl chain remodeling of CLBeta oxidation of hexanoyl-CoA to butanoyl-CoABeta oxidation of octanoyl-CoA to hexanoyl-CoABeta oxidation of decanoyl-CoA to octanoyl-CoA-CoABeta oxidation of lauroyl-CoA to decanoyl-CoA-CoA
MECANISMO DE DOENÇA

Mitochondrial trifunctional protein deficiency 1

An autosomal recessive metabolic disorder of long-chain fatty acid oxidation, biochemically characterized by loss of all enzyme activities of the mitochondrial trifunctional protein complex. The disease phenotype ranges from a fatal form characterized by early-onset cardiomyopathy, cardiac failure and early death to less severe, late-onset forms with myopathy, recurrent rhabdomyolysis, and sensorimotor axonal neuropathy as key features.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
343.5 TPM
Coração - Ventrículo esquerdo
215.7 TPM
Linfócitos
203.7 TPM
Fibroblastos
194.0 TPM
Esôfago - Muscular
182.5 TPM
OUTRAS DOENÇAS (4)
long chain 3-hydroxyacyl-CoA dehydrogenase deficiencymitochondrial trifunctional protein deficiency 1mitochondrial trifunctional protein deficiencyacute fatty liver of pregnancy
HGNC:4801UniProt:P40939
PMP22Peroxisomal membrane protein 2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Seems to be involved in pore-forming activity and may contribute to the unspecific permeability of the peroxisomal membrane

LOCALIZAÇÃO

Peroxisome membrane

VIAS BIOLÓGICAS (1)
EGR2 and SOX10-mediated initiation of Schwann cell myelination
EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
3229.9 TPM
Tecido adiposo
421.5 TPM
Cervix Ectocervix
415.8 TPM
Fallopian Tube
379.8 TPM
Cervix Endocervix
354.6 TPM
OUTRAS DOENÇAS (7)
Roussy-Levy syndromeCharcot-Marie-Tooth disease type 3hereditary neuropathy with liability to pressure palsiesCharcot-Marie-Tooth disease type 1E
HGNC:9118UniProt:Q9NR77
AIFM1Apoptosis-inducing factor 1, mitochondrialDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Functions both as NADH oxidoreductase and as regulator of apoptosis (PubMed:17094969, PubMed:20362274, PubMed:23217327, PubMed:33168626). In response to apoptotic stimuli, it is released from the mitochondrion intermembrane space into the cytosol and to the nucleus, where it functions as a proapoptotic factor in a caspase-independent pathway (PubMed:20362274). Release into the cytoplasm is mediated upon binding to poly-ADP-ribose chains (By similarity). The soluble form (AIFsol) found in the nuc

LOCALIZAÇÃO

Mitochondrion intermembrane spaceMitochondrion inner membraneCytoplasmNucleusCytoplasm, perinuclear regionMitochondrionCytoplasm, cytosol

MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 6

A mitochondrial disease resulting in a neurodegenerative disorder characterized by psychomotor delay, hypotonia, areflexia, muscle weakness and wasting. Some patients manifest prenatal ventriculomegaly and severe postnatal encephalomyopathy.

OUTRAS DOENÇAS (4)
X-linked hereditary sensory and autonomic neuropathy with hearing lossCharcot-Marie-Tooth disease X-linked recessive 4spondyloepimetaphyseal dysplasia, Bieganski typesevere X-linked mitochondrial encephalomyopathy
HGNC:8768UniProt:O95831
SETXHelicase senataxinDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

ATP-dependent 5'->3' DNA/RNA helicase that preferentially unwinds RNA substrates over DNA, playing a crucial role in resolving R-loops and promoting transcription termination (PubMed:36864660). Plays a role in transcription regulation by its ability to modulate RNA Polymerase II (Pol II) binding to chromatin and through its interaction with proteins involved in transcription (PubMed:19515850, PubMed:21700224). Contributes to the mRNA splicing efficiency and splice site selection (PubMed:19515850

LOCALIZAÇÃO

NucleusNucleus, nucleoplasmNucleus, nucleolusCytoplasmChromosomeChromosome, telomereCell projection, axonCell projection, growth cone

MECANISMO DE DOENÇA

Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2

A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAN2 is an autosomal recessive form associated with peripheral neuropathy and elevated serum alpha-fetoprotein, immunoglobulins and, less commonly, creatine kinase levels. Some SCAN2 patients manifest oculomotor apraxia.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
50.4 TPM
Linfócitos
39.4 TPM
Tireoide
36.1 TPM
Baço
32.8 TPM
Pulmão
25.9 TPM
OUTRAS DOENÇAS (2)
spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2amyotrophic lateral sclerosis type 4
HGNC:445UniProt:Q7Z333
SMN1Survival motor neuron proteinDisease-causing germline mutation(s) inDesconhecido
FUNÇÃO

The SMN complex catalyzes the assembly of small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome, and thereby plays an important role in the splicing of cellular pre-mRNAs (PubMed:18984161, PubMed:9845364). Most spliceosomal snRNPs contain a common set of Sm proteins SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE, SNRPF and SNRPG that assemble in a heptameric protein ring on the Sm site of the small nuclear RNA to form the core snRNP (Sm core) (PubMed:18984161). In the cytosol,

LOCALIZAÇÃO

Nucleus, gemNucleus, Cajal bodyCytoplasmCytoplasmic granulePerikaryonCell projection, neuron projectionCell projection, axonCytoplasm, myofibril, sarcomere, Z line

VIAS BIOLÓGICAS (2)
snRNP AssemblySARS-CoV-2 modulates host translation machinery
MECANISMO DE DOENÇA

Spinal muscular atrophy 1

A form of spinal muscular atrophy, a group of neuromuscular disorder characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. Autosomal recessive forms are classified according to the age of onset, the maximum muscular activity achieved, and survivorship. The severity of the disease is mainly determined by the copy number of SMN2, a copy gene which predominantly produces exon 7-skipped transcripts and only low amount of full-length transcripts that encode for a protein identical to SMN1. Only about 4% of SMA patients bear one SMN1 copy with an intragenic mutation. SMA1 is a severe form, with onset before 6 months of age. SMA1 patients never achieve the ability to sit.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
8.3 TPM
Linfócitos
7.8 TPM
Cervix Ectocervix
7.7 TPM
Cervix Endocervix
7.6 TPM
Útero
6.8 TPM
OUTRAS DOENÇAS (4)
spinal muscular atrophy, type IVspinal muscular atrophy, type 1spinal muscular atrophy, type IIspinal muscular atrophy, type III
HGNC:11117UniProt:Q16637
BSCL2SeipinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Plays a crucial role in the formation of lipid droplets (LDs) which are storage organelles at the center of lipid and energy homeostasis (PubMed:19278620, PubMed:21533227, PubMed:30293840, PubMed:31708432). In association with LDAF1, defines the sites of LD formation in the ER (PubMed:31708432). Also required for growth and maturation of small nascent LDs into larger mature LDs (PubMed:27564575). Mediates the formation and/or stabilization of endoplasmic reticulum-lipid droplets (ER-LD) contacts

LOCALIZAÇÃO

Endoplasmic reticulum membraneLipid droplet

MECANISMO DE DOENÇA

Lipodystrophy, congenital generalized, 2

A form of congenital generalized lipodystrophy, a metabolic disorder characterized by a near complete absence of adipose tissue, extreme insulin resistance, hypertriglyceridemia, hepatic steatosis and early onset of diabetes. Inheritance is autosomal recessive.

OUTRAS DOENÇAS (5)
hereditary spastic paraplegia 17severe neurodegenerative syndrome with lipodystrophyneuronopathy, distal hereditary motor, type 5Ccongenital generalized lipodystrophy type 2
HGNC:15832UniProt:Q96G97
KLHL7Kelch-like protein 7Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complex. The BCR(KLHL7) complex acts by mediating ubiquitination and subsequent degradation of substrate proteins. Probably mediates 'Lys-48'-linked ubiquitination

LOCALIZAÇÃO

NucleusCytoplasm

MECANISMO DE DOENÇA

Perching syndrome

An autosomal recessive multisystem disorder characterized by global developmental delay, dysmorphic facial features, feeding and respiratory difficulties with poor overall growth, axial hypotonia, and joint contractures. The features are variable, even within families, and may also include retinitis pigmentosa, cardiac or genitourinary anomalies, and abnormal sweating.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
28.9 TPM
Cérebro - Hemisfério cerebelar
19.6 TPM
Coração - Ventrículo esquerdo
16.2 TPM
Cerebelo
14.7 TPM
Fibroblastos
14.5 TPM
OUTRAS DOENÇAS (6)
PERCHING syndromeretinitis pigmentosa 42KLHL7-related cold-induced sweating-like syndromeKLHL7-related Bohring-Opitz-like syndrome
HGNC:15646UniProt:Q8IXQ5
KIF1AKinesin-like protein KIF1ADisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Kinesin motor with a plus-end-directed microtubule motor activity (By similarity). It is required for anterograde axonal transport of synaptic vesicle precursors (PubMed:33880452). Also required for neuronal dense core vesicles (DCVs) transport to the dendritic spines and axons. The interaction calcium-dependent with CALM1 increases vesicle motility and interaction with the scaffolding proteins PPFIA2 and TANC2 recruits DCVs to synaptic sites

LOCALIZAÇÃO

Cytoplasm, cytoskeletonCell projection, neuron projectionCell projection, axonCytoplasm, perinuclear regionSynapseCytoplasmic vesicle, secretory vesicle, neuronal dense core vesicle membrane

VIAS BIOLÓGICAS (2)
KinesinsCOPI-dependent Golgi-to-ER retrograde traffic
MECANISMO DE DOENÇA

Spastic paraplegia 30A, autosomal dominant

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. Some SPG30A patients have a pure form of the disorder, limited to spastic paraplegia, whereas others may have a complicated form that includes additional features such as cognitive dysfunction, learning disabilities, peripheral sensorimotor neuropathy, urinary sphincter problems, and/or cerebellar atrophy. SPG30A is characterized by onset in the first or second decades of unsteady spastic gait and hyperreflexia of the lower limbs. Inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Tecido-específico)
Córtex cerebral
331.8 TPM
Brain Frontal Cortex BA9
301.8 TPM
Cerebelo
266.3 TPM
Brain Anterior cingulate cortex BA24
262.4 TPM
Cérebro - Hemisfério cerebelar
235.1 TPM
OUTRAS DOENÇAS (5)
spastic paraplegia 30b, autosomal recessiveneuropathy, hereditary sensory, type 2Cintellectual disability, autosomal dominant 9hereditary sensory and autonomic neuropathy type 2
HGNC:888UniProt:Q12756
TRPV4Transient receptor potential cation channel subfamily V member 4Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Non-selective calcium permeant cation channel involved in osmotic sensitivity and mechanosensitivity (PubMed:16293632, PubMed:18695040, PubMed:18826956, PubMed:22526352, PubMed:23136043, PubMed:29899501). Activation by exposure to hypotonicity within the physiological range exhibits an outward rectification (PubMed:18695040, PubMed:18826956, PubMed:29899501). Also activated by heat, low pH, citrate and phorbol esters (PubMed:16293632, PubMed:18695040, PubMed:18826956, PubMed:20037586, PubMed:219

LOCALIZAÇÃO

Cell membraneApical cell membraneCell junction, adherens junctionCell projection, ciliumEndoplasmic reticulum

VIAS BIOLÓGICAS (2)
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cellsTRP channels
MECANISMO DE DOENÇA

Brachyolmia 3

A form of brachyolmia, a clinically and genetically heterogeneous skeletal dysplasia primarily affecting the spine and characterized by a short trunk, short stature, and platyspondyly. BCYM3 is an autosomal dominant form with severe scoliosis with or without kyphosis, and flattened irregular cervical vertebrae.

EXPRESSÃO TECIDUAL(Tecido-específico)
Glândula salivar
28.0 TPM
Esôfago - Mucosa
13.4 TPM
Rim - Córtex
13.3 TPM
Próstata
12.8 TPM
Skin Sun Exposed Lower leg
12.0 TPM
OUTRAS DOENÇAS (11)
spondyloepimetaphyseal dysplasia, Maroteaux typeneuronopathy, distal hereditary motor, autosomal dominant 8scapuloperoneal spinal muscular atrophy, autosomal dominantfamilial digital arthropathy-brachydactyly
HGNC:18083UniProt:Q9HBA0
DCTN1Dynactin subunit 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Part of the dynactin complex that activates the molecular motor dynein for ultra-processive transport along microtubules (By similarity). Plays a key role in dynein-mediated retrograde transport of vesicles and organelles along microtubules by recruiting and tethering dynein to microtubules. Binds to both dynein and microtubules providing a link between specific cargos, microtubules and dynein. Essential for targeting dynein to microtubule plus ends, recruiting dynein to membranous cargos and en

LOCALIZAÇÃO

CytoplasmCytoplasm, cytoskeletonCytoplasm, cytoskeleton, microtubule organizing center, centrosomeCytoplasm, cytoskeleton, microtubule organizing center, centrosome, centrioleCytoplasm, cytoskeleton, spindleNucleus envelopeCytoplasm, cell cortex

VIAS BIOLÓGICAS (5)
COPI-mediated anterograde transportHSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligandMHC class II antigen presentationCOPI-independent Golgi-to-ER retrograde trafficXBP1(S) activates chaperone genes
MECANISMO DE DOENÇA

Neuronopathy, distal hereditary motor, autosomal dominant 14

A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
212.6 TPM
Cerebelo
206.3 TPM
Brain Frontal Cortex BA9
173.9 TPM
Córtex cerebral
156.5 TPM
Pituitária
134.3 TPM
OUTRAS DOENÇAS (5)
neuronopathy, distal hereditary motor, type 7BPerry syndromeamyotrophic lateral sclerosisdistal hereditary motor neuropathy type 7
HGNC:2711UniProt:Q14203
EMILIN1EMILIN-1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in elastic and collagen fibers formation. It is required for EFEMP2 deposition into the extracellular matrix, and collagen network assembly and cross-linking via protein-lysine 6-oxidase/LOX activity (PubMed:36351433). May be responsible for anchoring smooth muscle cells to elastic fibers, and may be involved in the processes that regulate vessel assembly. Has cell adhesive capacity

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix

VIAS BIOLÓGICAS (1)
Molecules associated with elastic fibres
MECANISMO DE DOENÇA

Neuronopathy, distal hereditary motor, autosomal dominant 10

A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular diseases caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. HMND10 is characterized by length-dependent motor neuropathy primarily affecting the lower limbs, and onset of distal muscle weakness and atrophy in early childhood resulting in walking difficulties and gait abnormalities. Some affected individuals have pyramidal signs, including hyperreflexia. More variable features may include mild intellectual disability, minor gyration defects on brain imaging, foot deformities, and connective tissue defects.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
377.3 TPM
Cólon sigmoide
320.1 TPM
Aorta
311.6 TPM
Ovário
291.7 TPM
Artéria coronária
269.2 TPM
INTERAÇÕES PROTEICAS (5)
OUTRAS DOENÇAS (3)
neuronopathy, distal hereditary motor, autosomal dominant 10arterial tortuosity-bone fragility syndromeEMILIN-1-related connective tissue disease
HGNC:19880UniProt:Q9Y6C2
TYMPThymidine phosphorylaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May have a role in maintaining the integrity of the blood vessels. Has growth promoting activity on endothelial cells, angiogenic activity in vivo and chemotactic activity on endothelial cells in vitro Catalyzes the reversible phosphorolysis of thymidine. The produced molecules are then utilized as carbon and energy sources or in the rescue of pyrimidine bases for nucleotide synthesis

LOCALIZAÇÃO

VIAS BIOLÓGICAS (2)
Pyrimidine salvagePyrimidine catabolism
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 1, MNGIE type

A multisystem disease associated with mitochondrial dysfunction. It is clinically characterized by onset between the second and fifth decades of life, ptosis, progressive external ophthalmoplegia, gastrointestinal dysmotility (often pseudoobstruction), diffuse leukoencephalopathy, cachexia, peripheral neuropathy, and myopathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
330.6 TPM
Pulmão
260.6 TPM
Baço
215.3 TPM
Tecido adiposo
140.0 TPM
Adipose Visceral Omentum
116.4 TPM
OUTRAS DOENÇAS (2)
mitochondrial DNA depletion syndrome 1mitochondrial neurogastrointestinal encephalomyopathy
HGNC:3148UniProt:P19971
MMACHCCyanocobalamin reductase / alkylcobalamin dealkylaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Cobalamin (vitamin B12) cytosolic chaperone that catalyzes the reductive decyanation of cyanocob(III)alamin (cyanocobalamin, CNCbl) to yield cob(II)alamin and cyanide, using FAD or FMN as cofactors and NADPH as cosubstrate (PubMed:18779575, PubMed:19700356, PubMed:21697092, PubMed:25809485). Cyanocobalamin constitutes the inactive form of vitamin B12 introduced from the diet, and is converted into the active cofactors methylcobalamin (MeCbl) involved in methionine biosynthesis, and 5'-deoxyadeno

LOCALIZAÇÃO

Cytoplasm, cytosol

VIAS BIOLÓGICAS (2)
Cobalamin (Cbl) metabolismDefective MMADHC causes MMAHCD
MECANISMO DE DOENÇA

Methylmalonic aciduria and homocystinuria, cblC type

An autosomal recessive disorder of cobalamin metabolism characterized by decreased levels of the coenzymes adenosylcobalamin (AdoCbl) and methylcobalamin (MeCbl). Affected individuals may have developmental, hematologic, neurologic, metabolic, ophthalmologic, and dermatologic clinical findings. Although considered a disease of infancy or childhood, some individuals develop symptoms in adulthood.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
9.1 TPM
Testículo
7.5 TPM
Fibroblastos
6.7 TPM
Linfócitos
5.8 TPM
Glândula adrenal
4.4 TPM
OUTRAS DOENÇAS (1)
methylmalonic aciduria and homocystinuria type cblC
HGNC:24525UniProt:Q9Y4U1
PDHXPyruvate dehydrogenase protein X component, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Required for anchoring dihydrolipoamide dehydrogenase (E3) to the dihydrolipoamide transacetylase (E2) core of the pyruvate dehydrogenase complexes of eukaryotes. This specific binding is essential for a functional PDH complex

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (3)
Signaling by Retinoic AcidRegulation of pyruvate dehydrogenase (PDH) complexPDH complex synthesizes acetyl-CoA from PYR
MECANISMO DE DOENÇA

Pyruvate dehydrogenase E3-binding protein deficiency

A metabolic disorder characterized by decreased activity of the pyruvate dehydrogenase complex without observable reduction in the activities of enzymes E1, E2, or E3. Clinical features include hypotonia and psychomotor retardation.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
53.1 TPM
Coração - Ventrículo esquerdo
36.7 TPM
Testículo
34.8 TPM
Linfócitos
30.1 TPM
Cérebro - Hemisfério cerebelar
28.5 TPM
OUTRAS DOENÇAS (1)
pyruvate dehydrogenase E3-binding protein deficiency
HGNC:21350UniProt:O00330
GALCGalactocerebrosidaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Hydrolyzes the galactose ester bonds of glycolipids such as galactosylceramide and galactosylsphingosine (PubMed:8281145, PubMed:8399327). Enzyme with very low activity responsible for the lysosomal catabolism of galactosylceramide, a major lipid in myelin, kidney and epithelial cells of small intestine and colon (PubMed:8281145, PubMed:8399327)

LOCALIZAÇÃO

Lysosome

VIAS BIOLÓGICAS (1)
Glycosphingolipid catabolism
MECANISMO DE DOENÇA

Krabbe disease

An autosomal recessive disorder characterized by insufficient catabolism of several galactolipids that are important for normal myelin production. Four clinical forms are recognized. The infantile form accounts for 90% of cases. It manifests before six months of age with irritability, spasticity, arrest of motor and mental development, and bouts of temperature elevation without infection. This is followed by myoclonic jerks of arms and legs, oposthotonus, hypertonic fits, and mental regression, which progresses to a severe decerebrate condition with no voluntary movements and death from respiratory infections or cerebral hyperpyrexia before 2 years of age. Cases with later onset present with unexplained blindness, weakness and sensorimotor peripheral neuropathy, mental deterioration and death.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
31.7 TPM
Testículo
28.0 TPM
Brain Spinal cord cervical c-1
26.5 TPM
Pulmão
25.7 TPM
Ovário
22.2 TPM
OUTRAS DOENÇAS (4)
Krabbe diseaseinfantile Krabbe diseaseadult Krabbe diseaselate-infantile/juvenile Krabbe disease
HGNC:4115UniProt:P54803
NTRK1High affinity nerve growth factor receptorDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Receptor tyrosine kinase involved in the development and the maturation of the central and peripheral nervous systems through regulation of proliferation, differentiation and survival of sympathetic and nervous neurons. High affinity receptor for NGF which is its primary ligand (PubMed:1281417, PubMed:15488758, PubMed:17196528, PubMed:1849459, PubMed:1850821, PubMed:22649032, PubMed:27445338, PubMed:8325889). Can also bind and be activated by NTF3/neurotrophin-3. However, NTF3 only supports axon

LOCALIZAÇÃO

Cell membraneEarly endosome membraneLate endosome membraneRecycling endosome membrane

VIAS BIOLÓGICAS (1)
TRKA activation by NGF
MECANISMO DE DOENÇA

Congenital insensitivity to pain with anhidrosis

Characterized by a congenital insensitivity to pain, anhidrosis (absence of sweating), absence of reaction to noxious stimuli, self-mutilating behavior, and intellectual disability. This rare autosomal recessive disorder is also known as congenital sensory neuropathy with anhidrosis or hereditary sensory and autonomic neuropathy type IV or familial dysautonomia type II.

EXPRESSÃO TECIDUAL(Tecido-específico)
Próstata
5.7 TPM
Testículo
4.9 TPM
Cervix Endocervix
4.3 TPM
Útero
3.7 TPM
Fallopian Tube
3.5 TPM
OUTRAS DOENÇAS (4)
hereditary sensory and autonomic neuropathy type 4hereditary sensory and autonomic neuropathy type 5familial medullary thyroid carcinomadifferentiated thyroid carcinoma
HGNC:8031UniProt:P04629
CD59CD59 glycoproteinDisease-causing germline mutation(s) inModerado
FUNÇÃO

Potent inhibitor of the complement membrane attack complex (MAC) action, which protects human cells from damage during complement activation (PubMed:11882685, PubMed:1698710, PubMed:2475111, PubMed:2475570, PubMed:2606909, PubMed:9053451). Acts by binding to the beta-haipins of C8 (C8A and C8B) components of the assembling MAC, forming an intermolecular beta-sheet that prevents incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore (PubMed:11882685, PubM

LOCALIZAÇÃO

Cell membraneSecreted

VIAS BIOLÓGICAS (2)
Regulation of Complement cascadeNeutrophil degranulation
MECANISMO DE DOENÇA

Hemolytic anemia, CD59-mediated, with or without polyneuropathy

An autosomal recessive disorder characterized by infantile onset of chronic hemolysis and a relapsing-remitting polyneuropathy, often exacerbated by infection, and manifested as hypotonia, limb muscle weakness, and hyporeflexia.

OUTRAS DOENÇAS (1)
primary CD59 deficiency
HGNC:1689UniProt:P13987
DLDDihydrolipoyl dehydrogenase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Lipoamide dehydrogenase is a component of the glycine cleavage system as well as an E3 component of three alpha-ketoacid dehydrogenase complexes (pyruvate-, alpha-ketoglutarate-, and branched-chain amino acid-dehydrogenase complex) (PubMed:15712224, PubMed:16442803, PubMed:16770810, PubMed:17404228, PubMed:20160912, PubMed:20385101). The 2-oxoglutarate dehydrogenase complex is mainly active in the mitochondrion (PubMed:29211711). A fraction of the 2-oxoglutarate dehydrogenase complex also locali

LOCALIZAÇÃO

Mitochondrion matrixNucleusCell projection, cilium, flagellumCytoplasmic vesicle, secretory vesicle, acrosome

VIAS BIOLÓGICAS (10)
BCKDH synthesizes BCAA-CoA from KIC, KMVA, KIVBranched-chain amino acid catabolismBranched-chain ketoacid dehydrogenase kinase deficiencyH139Hfs13* PPM1K causes a mild variant of MSUDSignaling by Retinoic Acid
MECANISMO DE DOENÇA

Dihydrolipoamide dehydrogenase deficiency

An autosomal recessive metabolic disorder characterized biochemically by a combined deficiency of the branched-chain alpha-keto acid dehydrogenase complex (BCKDC), pyruvate dehydrogenase complex (PDC), and alpha-ketoglutarate dehydrogenase complex (KGDC). Clinically, affected individuals have lactic acidosis and neurologic deterioration due to sensitivity of the central nervous system to defects in oxidative metabolism.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
73.2 TPM
Coração - Ventrículo esquerdo
70.7 TPM
Músculo esquelético
69.5 TPM
Esôfago - Muscular
69.5 TPM
Glândula adrenal
69.1 TPM
OUTRAS DOENÇAS (1)
pyruvate dehydrogenase E3 deficiency
HGNC:2898UniProt:P09622
PDHA1Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrialDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Together with PDHB forms the heterotetrameric E1 subunit of the pyruvate dehydrogenase (PDH) complex (PubMed:17474719, PubMed:19081061). The PDH complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2), and thereby links cytoplasmic glycolysis and the mitochondrial tricarboxylic acid (TCA) cycle (PubMed:19081061, PubMed:7782287). It contains multiple copies of three enzymatic components: pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and dihydrolipoamide

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (4)
Signaling by Retinoic AcidRegulation of pyruvate dehydrogenase (PDH) complexPDH complex synthesizes acetyl-CoA from PYRMitochondrial protein degradation
MECANISMO DE DOENÇA

Pyruvate dehydrogenase E1-alpha deficiency

An enzymatic defect causing primary lactic acidosis in children. It is associated with a broad clinical spectrum ranging from fatal lactic acidosis in the newborn to chronic neurologic dysfunction with structural abnormalities in the central nervous system without systemic acidosis.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
136.8 TPM
Coração - Átrio
101.8 TPM
Músculo esquelético
97.1 TPM
Rim - Medula
76.9 TPM
Linfócitos
70.4 TPM
OUTRAS DOENÇAS (2)
pyruvate dehydrogenase E1-alpha deficiencypyruvate dehydrogenase deficiency
HGNC:8806UniProt:P08559
PEX10Peroxisome biogenesis factor 10Disease-causing germline mutation(s) inTolerante
FUNÇÃO

E3 ubiquitin-protein ligase component of a retrotranslocation channel required for peroxisome organization by mediating export of the PEX5 receptor from peroxisomes to the cytosol, thereby promoting PEX5 recycling (PubMed:24662292). The retrotranslocation channel is composed of PEX2, PEX10 and PEX12; each subunit contributing transmembrane segments that coassemble into an open channel that specifically allows the passage of PEX5 through the peroxisomal membrane (By similarity). PEX10 also regula

LOCALIZAÇÃO

Peroxisome membrane

VIAS BIOLÓGICAS (2)
Peroxisomal protein importE3 ubiquitin ligases ubiquitinate target proteins
MECANISMO DE DOENÇA

Peroxisome biogenesis disorder complementation group 7

A peroxisomal disorder arising from a failure of protein import into the peroxisomal membrane or matrix. The peroxisome biogenesis disorders (PBD group) are genetically heterogeneous with at least 14 distinct genetic groups as concluded from complementation studies. Include disorders are: Zellweger syndrome (ZWS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and classical rhizomelic chondrodysplasia punctata (RCDP). ZWS, NALD and IRD are distinct from RCDP and constitute a clinical continuum of overlapping phenotypes known as the Zellweger spectrum (PBD-ZSS).

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
33.5 TPM
Glândula adrenal
23.3 TPM
Brain Spinal cord cervical c-1
22.1 TPM
Nervo tibial
20.8 TPM
Fibroblastos
20.1 TPM
OUTRAS DOENÇAS (5)
peroxisome biogenesis disorder 6Bperoxisome biogenesis disorder 6A (Zellweger)autosomal recessive ataxia due to PEX10 deficiencyZellweger spectrum disorders
HGNC:8851UniProt:O60683
PEX14Peroxisomal membrane protein PEX14Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Component of the PEX13-PEX14 docking complex, a translocon channel that specifically mediates the import of peroxisomal cargo proteins bound to PEX5 receptor (PubMed:24235149, PubMed:28765278, PubMed:9653144). The PEX13-PEX14 docking complex forms a large import pore which can be opened to a diameter of about 9 nm (By similarity). Mechanistically, PEX5 receptor along with cargo proteins associates with the PEX14 subunit of the PEX13-PEX14 docking complex in the cytosol, leading to the insertion

LOCALIZAÇÃO

Peroxisome membrane

VIAS BIOLÓGICAS (3)
Peroxisomal protein importE3 ubiquitin ligases ubiquitinate target proteinsClass I peroxisomal membrane protein import
MECANISMO DE DOENÇA

Peroxisome biogenesis disorder complementation group K

A peroxisomal disorder arising from a failure of protein import into the peroxisomal membrane or matrix. The peroxisome biogenesis disorders (PBD group) are genetically heterogeneous with at least 14 distinct genetic groups as concluded from complementation studies. Include disorders are: Zellweger syndrome (ZWS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and classical rhizomelic chondrodysplasia punctata (RCDP). ZWS, NALD and IRD are distinct from RCDP and constitute a clinical continuum of overlapping phenotypes known as the Zellweger spectrum (PBD-ZSS).

EXPRESSÃO TECIDUAL(Ubíquo)
Bladder
54.7 TPM
Próstata
39.8 TPM
Útero
31.9 TPM
Brain Frontal Cortex BA9
30.1 TPM
Testículo
29.2 TPM
OUTRAS DOENÇAS (3)
peroxisome biogenesis disorder 13A (Zellweger)Zellweger spectrum disordersobsolete neonatal adrenoleukodystrophy
HGNC:8856UniProt:O75381
SCN11ASodium channel protein type 11 subunit alphaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Sodium channel mediating the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient (PubMed:10580103, PubMed:12384689, PubMed:24036948, PubMed:24776970, PubMed:25791876, PubMed:26645915). Involved in membrane depolarization during action potential in nocicepto

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
Interaction between L1 and AnkyrinsPhase 0 - rapid depolarisation
MECANISMO DE DOENÇA

Neuropathy, hereditary sensory and autonomic, 7

A form of hereditary sensory and autonomic neuropathy, a genetically and clinically heterogeneous group of disorders characterized by degeneration of dorsal root and autonomic ganglion cells, and by sensory and/or autonomic abnormalities. HSAN7 is characterized by congenital inability to experience pain resulting in self-mutilations, slow-healing wounds, and multiple painless fractures. mild muscle weakness, delayed motor development, slightly reduced motor and sensory nerve conduction velocities, hyperhidrosis and gastrointestinal dysfunction.

EXPRESSÃO TECIDUAL(Baixa expressão)
Baço
3.3 TPM
Testículo
3.0 TPM
Cólon sigmoide
1.1 TPM
Nervo tibial
0.8 TPM
Tecido adiposo
0.7 TPM
OUTRAS DOENÇAS (6)
hereditary sensory and autonomic neuropathy type 7familial episodic pain syndrome with predominantly lower limb involvementparoxysmal extreme pain disorderchannelopathy-associated congenital insensitivity to pain, autosomal recessive
HGNC:10583UniProt:Q9UI33
REEP1Receptor expression-enhancing protein 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Required for endoplasmic reticulum (ER) network formation, shaping and remodeling; it links ER tubules to the cytoskeleton. May also enhance the cell surface expression of odorant receptors (PubMed:20200447). May play a role in long-term axonal maintenance (PubMed:24478229)

LOCALIZAÇÃO

MembraneMitochondrion membraneEndoplasmic reticulum

VIAS BIOLÓGICAS (1)
Expression and translocation of olfactory receptors
MECANISMO DE DOENÇA

Spastic paraplegia 31, autosomal dominant

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
67.0 TPM
Cólon sigmoide
61.1 TPM
Esôfago - Muscular
51.8 TPM
Esôfago - Junção
44.2 TPM
Artéria tibial
35.6 TPM
OUTRAS DOENÇAS (4)
hereditary spastic paraplegia 31spinal muscular atrophy, distal, autosomal recessive, 6neuronopathy, distal hereditary motor, type 5Bneuronopathy, distal hereditary motor, type 5
HGNC:25786UniProt:Q9H902
RTN2Reticulon-2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Inhibits amyloid precursor protein processing, probably by blocking BACE1 activity (PubMed:15286784). Enhances trafficking of the glutamate transporter SLC1A1/EAAC1 from the endoplasmic reticulum to the cell surface (By similarity). Plays a role in the translocation of SLC2A4/GLUT4 from intracellular membranes to the cell membrane which facilitates the uptake of glucose into the cell (By similarity)

LOCALIZAÇÃO

Endoplasmic reticulum membraneSarcoplasmic reticulum membraneCell membraneCell membrane, sarcolemmaCell membrane, sarcolemma, T-tubuleCytoplasm, myofibril, sarcomere, Z lineCytoplasm, cytoskeleton

MECANISMO DE DOENÇA

Spastic paraplegia 12, autosomal dominant

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
105.9 TPM
Brain Frontal Cortex BA9
49.2 TPM
Córtex cerebral
48.2 TPM
Cerebelo
40.6 TPM
Cérebro - Hemisfério cerebelar
40.1 TPM
OUTRAS DOENÇAS (2)
neuronopathy, distal hereditary motor, autosomal recessive 11, with spasticityhereditary spastic paraplegia 12
HGNC:10468UniProt:O75298
LRPPRCLeucine-rich PPR motif-containing protein, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May play a role in RNA metabolism in both nuclei and mitochondria. In the nucleus binds to HNRPA1-associated poly(A) mRNAs and is part of nmRNP complexes at late stages of mRNA maturation which are possibly associated with nuclear mRNA export. Positively modulates nuclear export of mRNAs containing the EIF4E sensitivity element (4ESE) by binding simultaneously to both EIF4E and the 4ESE and acting as a platform for assembly for the RNA export complex (PubMed:19262567, PubMed:28325843). Also bind

LOCALIZAÇÃO

MitochondrionNucleusNucleus, nucleoplasmNucleus inner membraneNucleus outer membrane

VIAS BIOLÓGICAS (2)
Mitochondrial mRNA modificationMitochondrial RNA degradation
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency, nuclear type 5

An autosomal recessive, severe mitochondrial disease with multisystemic manifestations and early onset. Clinical features include delayed psychomotor development, impaired intellectual development with speech delay, mild dysmorphic facial features, hypotonia, ataxia, and seizures. Brain imaging shows bilaterally symmetrical necrotic lesions in subcortical brain regions. Mortality is high, due to episodes of severe metabolic acidosis and coma.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
113.8 TPM
Cérebro - Hemisfério cerebelar
71.9 TPM
Fibroblastos
69.4 TPM
Músculo esquelético
59.7 TPM
Cerebelo
56.5 TPM
OUTRAS DOENÇAS (1)
congenital lactic acidosis, Saguenay-Lac-Saint-Jean type
HGNC:15714UniProt:P42704
CNTNAP1Contactin-associated protein 1Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Required, with CNTNAP2, for radial and longitudinal organization of myelinated axons. Plays a role in the formation of functional distinct domains critical for saltatory conduction of nerve impulses in myelinated nerve fibers. Demarcates the paranodal region of the axo-glial junction. In association with contactin involved in the signaling between axons and myelinating glial cells

LOCALIZAÇÃO

MembraneCell junction, paranodal septate junction

VIAS BIOLÓGICAS (1)
Neurofascin interactions
MECANISMO DE DOENÇA

Lethal congenital contracture syndrome 7

A form of lethal congenital contracture syndrome, an autosomal recessive disorder characterized by degeneration of anterior horn neurons, extreme skeletal muscle atrophy and congenital non-progressive joint contractures. The contractures can involve the upper or lower limbs and/or the vertebral column, leading to various degrees of flexion or extension limitations evident at birth. LCCS7 is a severe axoglial disease characterized by congenital distal joint contractures, polyhydramnios, reduced fetal movements, and motor paralysis leading to death early in the neonatal period.

VIAS REACTOME (1)
OUTRAS DOENÇAS (2)
neuropathy, congenital hypomyelinating, 3lethal congenital contracture syndrome 7
HGNC:8011UniProt:P78357
BICD2Protein bicaudal D homolog 2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Acts as an adapter protein linking the dynein motor complex to various cargos and converts dynein from a non-processive to a highly processive motor in the presence of dynactin. Facilitates and stabilizes the interaction between dynein and dynactin and activates dynein processivity (the ability to move along a microtubule for a long distance without falling off the track) (PubMed:25814576). Facilitates the binding of RAB6A to the Golgi by stabilizing its GTP-bound form. Regulates coat complex co

LOCALIZAÇÃO

Golgi apparatusCytoplasm, cytoskeletonCytoplasmNucleus envelopeNucleus, nuclear pore complex

VIAS BIOLÓGICAS (1)
COPI-independent Golgi-to-ER retrograde traffic
MECANISMO DE DOENÇA

Spinal muscular atrophy, lower extremity-predominant 2A, childhood onset, autosomal dominant

An autosomal dominant form of spinal muscular atrophy characterized by early-childhood onset of muscle weakness and atrophy predominantly affecting the proximal and distal muscles of the lower extremity, although some patients may show upper extremity involvement. The disorder results in delayed walking, waddling gait, difficulty walking, and loss of distal reflexes. Some patients may have foot deformities or hyperlordosis, and some show mild upper motor signs, such as spasticity. Sensation, bulbar function, and cognitive function are preserved. The disorder shows very slow progression throughout life.

OUTRAS DOENÇAS (2)
autosomal dominant childhood-onset proximal spinal muscular atrophy with contracturesspinal muscular atrophy, lower extremity-predominant, 2b, prenatal onset, autosomal dominant
HGNC:17208UniProt:Q8TD16
PEX5Peroxisomal targeting signal 1 receptorDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Receptor that mediates peroxisomal import of proteins containing a C-terminal PTS1-type tripeptide peroxisomal targeting signal (SKL-type) (PubMed:11101887, PubMed:11336669, PubMed:12456682, PubMed:16314507, PubMed:17157249, PubMed:17428317, PubMed:21976670, PubMed:26344566, PubMed:7706321, PubMed:7719337, PubMed:7790377). Binds to cargo proteins containing a PTS1 peroxisomal targeting signal in the cytosol, and translocates them into the peroxisome matrix by passing through the PEX13-PEX14 dock

LOCALIZAÇÃO

Cytoplasm, cytosolPeroxisome matrix

VIAS BIOLÓGICAS (1)
Pexophagy
MECANISMO DE DOENÇA

Peroxisome biogenesis disorder 2A

A fatal peroxisome biogenesis disorder belonging to the Zellweger disease spectrum and characterized clinically by severe neurologic dysfunction with profound psychomotor retardation, severe hypotonia and neonatal seizures, craniofacial abnormalities, liver dysfunction, and biochemically by the absence of peroxisomes. Additional features include cardiovascular and skeletal defects, renal cysts, ocular abnormalities, and hearing impairment. Most severely affected individuals with the classic form of the disease (classic Zellweger syndrome) die within the first year of life.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
77.7 TPM
Cerebelo
49.0 TPM
Cérebro - Hemisfério cerebelar
48.3 TPM
Pituitária
46.8 TPM
Nervo tibial
44.2 TPM
OUTRAS DOENÇAS (5)
peroxisome biogenesis disorder 2Brhizomelic chondrodysplasia punctata type 5peroxisome biogenesis disorder 2A (Zellweger)Zellweger spectrum disorders
HGNC:9719UniProt:P50542
SLC25A46Mitochondrial outer membrane protein SLC25A46Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Transmembrane protein of the mitochondrial outer membrane that controls mitochondrial organization (PubMed:26168012, PubMed:27390132, PubMed:27543974). May regulate the assembly of the MICOS (mitochondrial contact site and cristae organizing system) complex which is essential to the biogenesis and dynamics of mitochondrial cristae, the inwards folds of the inner mitochondrial membrane (PubMed:27390132). Through its interaction with the EMC (endoplasmic reticulum membrane protein complex), could

LOCALIZAÇÃO

Mitochondrion outer membrane

MECANISMO DE DOENÇA

Neuropathy, hereditary motor and sensory, 6B, with optic atrophy

An autosomal recessive neurologic disorder characterized by early-onset optic atrophy, progressive visual loss, and peripheral sensorimotor neuropathy manifesting as axonal Charcot-Marie-Tooth disease, with variable age at onset and severity. Charcot-Marie-Tooth disease is a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. It is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies and primary peripheral axonal neuropathies. Peripheral axonal neuropathies are characterized by signs of axonal regeneration in the absence of obvious myelin alterations, and normal or slightly reduced nerve conduction velocities.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
35.0 TPM
Cérebro - Hemisfério cerebelar
31.7 TPM
Fibroblastos
27.1 TPM
Cerebelo
25.2 TPM
Nervo tibial
21.7 TPM
INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (4)
neuropathy, hereditary motor and sensory, type 6Bpontocerebellar hypoplasia, type 1Epontocerebellar hypoplasia type 1hereditary motor and sensory neuropathy type 6
HGNC:25198UniProt:Q96AG3
IGHMBP2DNA-binding protein SMUBP-2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

5' to 3' helicase that unwinds RNA and DNA duplexes in an ATP-dependent reaction (PubMed:19158098, PubMed:22999958, PubMed:30218034). Specific to 5'-phosphorylated single-stranded guanine-rich sequences (PubMed:22999958, PubMed:8349627). May play a role in RNA metabolism, ribosome biogenesis or initiation of translation (PubMed:19158098, PubMed:19299493). May play a role in regulation of transcription (By similarity). Interacts with tRNA-Tyr (PubMed:19299493)

LOCALIZAÇÃO

NucleusCytoplasmCell projection, axon

MECANISMO DE DOENÇA

Neuronopathy, distal hereditary motor, autosomal recessive 1

A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
48.4 TPM
Cólon sigmoide
33.5 TPM
Esôfago - Junção
31.9 TPM
Útero
29.7 TPM
Cerebelo
29.6 TPM
OUTRAS DOENÇAS (2)
autosomal recessive distal spinal muscular atrophy 1Charcot-Marie-Tooth disease axonal type 2S
HGNC:5542UniProt:P38935
WARS1Tryptophan--tRNA ligase, cytoplasmicDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Catalyzes the attachment of tryptophan to tRNA(Trp) in a two-step reaction: tryptophan is first activated by ATP to form Trp-AMP and then transferred to the acceptor end of the tRNA(Trp) Has no angiostatic activity Possesses an angiostatic activity but has no aminoacylation activity (PubMed:11773625, PubMed:11773626, PubMed:14630953). Inhibits fluid shear stress-activated responses of endothelial cells (PubMed:14630953). Regulates ERK, Akt, and eNOS activation pathways that are associated with a

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Cytosolic tRNA aminoacylation
MECANISMO DE DOENÇA

Neuronopathy, distal hereditary motor, autosomal dominant 9

A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs. HMND9 is characterized by juvenile onset of slowly progressive distal muscle weakness and atrophy affecting both the lower and upper limbs.

OUTRAS DOENÇAS (4)
neuronopathy, distal hereditary motor, type 9neurodevelopmental disorder with microcephaly and speech delay, with or without brain abnormalitiesautosomal recessive primary microcephalycomplex neurodevelopmental disorder
HGNC:12729UniProt:P23381
POLGDNA polymerase subunit gamma-1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalytic subunit of DNA polymerase gamma solely responsible for replication of mitochondrial DNA (mtDNA). Replicates both heavy and light strands of the circular mtDNA genome using a single-stranded DNA template, RNA primers and the four deoxyribonucleoside triphosphates as substrates (PubMed:11477093, PubMed:11897778, PubMed:15917273, PubMed:19837034, PubMed:9558343). Has 5' -> 3' polymerase activity. Functionally interacts with TWNK and SSBP1 at the replication fork to form a highly processiv

LOCALIZAÇÃO

MitochondrionMitochondrion matrix, mitochondrion nucleoid

VIAS BIOLÓGICAS (1)
Strand-asynchronous mitochondrial DNA replication
MECANISMO DE DOENÇA

Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 1

A disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
48.3 TPM
Linfócitos
42.0 TPM
Baço
41.5 TPM
Útero
40.9 TPM
Pulmão
38.7 TPM
OUTRAS DOENÇAS (11)
sensory ataxic neuropathy, dysarthria, and ophthalmoparesismitochondrial DNA depletion syndrome 4bmitochondrial DNA depletion syndrome 4amitochondrial disease
HGNC:9179UniProt:P54098
PRDX1Peroxiredoxin-1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Thiol-specific peroxidase that catalyzes the reduction of hydrogen peroxide and organic hydroperoxides to water and alcohols, respectively. Plays a role in cell protection against oxidative stress by detoxifying peroxides and as sensor of hydrogen peroxide-mediated signaling events. Might participate in the signaling cascades of growth factors and tumor necrosis factor-alpha by regulating the intracellular concentrations of H(2)O(2) (PubMed:9497357). Reduces an intramolecular disulfide bond in G

LOCALIZAÇÃO

CytoplasmMelanosome

VIAS BIOLÓGICAS (4)
TP53 Regulates Metabolic GenesNFE2L2 regulating anti-oxidant/detoxification enzymesDetoxification of Reactive Oxygen SpeciesDeregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Mucosa
790.6 TPM
Tireoide
635.9 TPM
Linfócitos
598.5 TPM
Fibroblastos
487.5 TPM
Brain Spinal cord cervical c-1
472.8 TPM
OUTRAS DOENÇAS (1)
methylmalonic aciduria and homocystinuria type cblC
HGNC:HGNC:9352UniProt:Q06830
HEXABeta-hexosaminidase subunit alphaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Hydrolyzes the non-reducing end N-acetyl-D-hexosamine and/or sulfated N-acetyl-D-hexosamine of glycoconjugates, such as the oligosaccharide moieties from proteins and neutral glycolipids, or from certain mucopolysaccharides (PubMed:11707436, PubMed:8123671, PubMed:8672428, PubMed:9694901). The isozyme S is as active as the isozyme A on the anionic bis-sulfated glycans, the chondroitin-6-sulfate trisaccharide (C6S-3), and the dermatan sulfate pentasaccharide, and the sulfated glycosphingolipid SM

LOCALIZAÇÃO

Lysosome

VIAS BIOLÓGICAS (1)
Defective HEXA causes GM2G1 (Hyaluronan metabolism)
MECANISMO DE DOENÇA

GM2-gangliosidosis 1

An autosomal recessive lysosomal storage disease marked by the accumulation of GM2 gangliosides in the neuronal cells. It is characterized by GM2 gangliosides accumulation in the absence of HEXA activity, leading to neurodegeneration and, in the infantile form, death in early childhood. It exists in several forms: infantile (most common and most severe), juvenile and adult (late-onset).

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
43.9 TPM
Fibroblastos
39.7 TPM
Cervix Endocervix
36.7 TPM
Aorta
36.0 TPM
Pulmão
34.0 TPM
OUTRAS DOENÇAS (4)
Tay-Sachs diseaseTay-Sachs disease, b variant, infantile formTay-Sachs disease, B variant, adult formTay-Sachs disease, b variant, juvenile form
HGNC:4878UniProt:P06865
CHCHD10Coiled-coil-helix-coiled-coil-helix domain-containing protein 10, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May be involved in the maintenance of mitochondrial organization and mitochondrial cristae structure

LOCALIZAÇÃO

Mitochondrion intermembrane space

VIAS BIOLÓGICAS (1)
Mitochondrial protein import
MECANISMO DE DOENÇA

Frontotemporal dementia and/or amyotrophic lateral sclerosis 2

A neurodegenerative disorder characterized by frontotemporal dementia and/or amyotrophic lateral sclerosis in affected individuals. There is high intrafamilial variation. Frontotemporal dementia is characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Amyotrophic lateral sclerosis is characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis.

OUTRAS DOENÇAS (5)
lower motor neuron syndrome with late-adult onsetfrontotemporal dementia and/or amyotrophic lateral sclerosis 2autosomal dominant mitochondrial myopathy with exercise intoleranceamyotrophic lateral sclerosis
HGNC:15559UniProt:Q8WYQ3
PEX16Peroxisomal membrane protein PEX16Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Required for peroxisome membrane biogenesis. May play a role in early stages of peroxisome assembly. Can recruit other peroxisomal proteins, such as PEX3 and PMP34, to de novo peroxisomes derived from the endoplasmic reticulum (ER). May function as receptor for PEX3

LOCALIZAÇÃO

Peroxisome membrane

VIAS BIOLÓGICAS (1)
Class I peroxisomal membrane protein import
MECANISMO DE DOENÇA

Peroxisome biogenesis disorder complementation group 9

A peroxisomal disorder arising from a failure of protein import into the peroxisomal membrane or matrix. The peroxisome biogenesis disorders (PBD group) are genetically heterogeneous with at least 14 distinct genetic groups as concluded from complementation studies. Include disorders are: Zellweger syndrome (ZWS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and classical rhizomelic chondrodysplasia punctata (RCDP). ZWS, NALD and IRD are distinct from RCDP and constitute a clinical continuum of overlapping phenotypes known as the Zellweger spectrum (PBD-ZSS).

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
31.4 TPM
Testículo
30.9 TPM
Tireoide
24.5 TPM
Nervo tibial
23.1 TPM
Brain Spinal cord cervical c-1
22.4 TPM
OUTRAS DOENÇAS (5)
peroxisome biogenesis disorder 8A (Zellweger)peroxisome biogenesis disorder 8BZellweger spectrum disordersobsolete neonatal adrenoleukodystrophy
HGNC:8857UniProt:Q9Y5Y5
PEX6Peroxisomal ATPase PEX6Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the PEX1-PEX6 AAA ATPase complex, a protein dislocase complex that mediates the ATP-dependent extraction of the PEX5 receptor from peroxisomal membranes, an essential step for PEX5 recycling (PubMed:16314507, PubMed:16854980, PubMed:21362118, PubMed:29884772). Specifically recognizes PEX5 monoubiquitinated at 'Cys-11', and pulls it out of the peroxisome lumen through the PEX2-PEX10-PEX12 retrotranslocation channel (PubMed:29884772). Extraction by the PEX1-PEX6 AAA ATPase complex is

LOCALIZAÇÃO

Cytoplasm, cytosolPeroxisome membraneCell projection, cilium, photoreceptor outer segment

VIAS BIOLÓGICAS (1)
Peroxisomal protein import
MECANISMO DE DOENÇA

Peroxisome biogenesis disorder complementation group 4

A peroxisomal disorder arising from a failure of protein import into the peroxisomal membrane or matrix. The peroxisome biogenesis disorders (PBD group) are genetically heterogeneous with at least 14 distinct genetic groups as concluded from complementation studies. Include disorders are: Zellweger syndrome (ZWS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and classical rhizomelic chondrodysplasia punctata (RCDP). ZWS, NALD and IRD are distinct from RCDP and constitute a clinical continuum of overlapping phenotypes known as the Zellweger spectrum (PBD-ZSS).

EXPRESSÃO TECIDUAL(Ubíquo)
Fallopian Tube
66.8 TPM
Ovário
64.6 TPM
Cerebelo
61.1 TPM
Cérebro - Hemisfério cerebelar
58.5 TPM
Pituitária
55.1 TPM
OUTRAS DOENÇAS (6)
peroxisome biogenesis disorder 4Bperoxisome biogenesis disorder 4A (Zellweger)peroxisome biogenesis disorder due to PEX6 defectobsolete Heimler syndrome
HGNC:8859UniProt:Q13608
PEX12Peroxisome assembly protein 12Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of a retrotranslocation channel required for peroxisome organization by mediating export of the PEX5 receptor from peroxisomes to the cytosol, thereby promoting PEX5 recycling (PubMed:24662292, PubMed:9354782, PubMed:9632816). The retrotranslocation channel is composed of PEX2, PEX10 and PEX12; each subunit contributing transmembrane segments that coassemble into an open channel that specifically allows the passage of PEX5 through the peroxisomal membrane (By similarity). PEX12 also re

LOCALIZAÇÃO

Peroxisome membrane

VIAS BIOLÓGICAS (3)
Peroxisomal protein importE3 ubiquitin ligases ubiquitinate target proteinsClass I peroxisomal membrane protein import
MECANISMO DE DOENÇA

Peroxisome biogenesis disorder complementation group 3

A peroxisomal disorder arising from a failure of protein import into the peroxisomal membrane or matrix. The peroxisome biogenesis disorders (PBD group) are genetically heterogeneous with at least 14 distinct genetic groups as concluded from complementation studies. Include disorders are: Zellweger syndrome (ZWS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and classical rhizomelic chondrodysplasia punctata (RCDP). ZWS, NALD and IRD are distinct from RCDP and constitute a clinical continuum of overlapping phenotypes known as the Zellweger spectrum (PBD-ZSS).

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
12.5 TPM
Fibroblastos
11.2 TPM
Pituitária
10.1 TPM
Glândula adrenal
9.2 TPM
Nervo tibial
9.2 TPM
OUTRAS DOENÇAS (4)
peroxisome biogenesis disorder type 3Bperoxisome biogenesis disorder 3A (Zellweger)Zellweger spectrum disordersobsolete neonatal adrenoleukodystrophy
HGNC:8854UniProt:O00623
PEX1Peroxisomal ATPase PEX1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the PEX1-PEX6 AAA ATPase complex, a protein dislocase complex that mediates the ATP-dependent extraction of the PEX5 receptor from peroxisomal membranes, an essential step for PEX5 recycling (PubMed:11439091, PubMed:16314507, PubMed:16854980, PubMed:21362118, PubMed:29884772). Specifically recognizes PEX5 monoubiquitinated at 'Cys-11', and pulls it out of the peroxisome lumen through the PEX2-PEX10-PEX12 retrotranslocation channel (PubMed:29884772). Extraction by the PEX1-PEX6 AAA A

LOCALIZAÇÃO

Cytoplasm, cytosolPeroxisome membrane

VIAS BIOLÓGICAS (1)
Peroxisomal protein import
MECANISMO DE DOENÇA

Peroxisome biogenesis disorder complementation group 1

A peroxisomal disorder arising from a failure of protein import into the peroxisomal membrane or matrix. The peroxisome biogenesis disorders (PBD group) are genetically heterogeneous with at least 14 distinct genetic groups as concluded from complementation studies. Include disorders are: Zellweger syndrome (ZWS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and classical rhizomelic chondrodysplasia punctata (RCDP). ZWS, NALD and IRD are distinct from RCDP and constitute a clinical continuum of overlapping phenotypes known as the Zellweger spectrum (PBD-ZSS).

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
23.8 TPM
Nervo tibial
23.3 TPM
Cervix Endocervix
23.1 TPM
Tireoide
21.9 TPM
Cerebelo
21.8 TPM
OUTRAS DOENÇAS (6)
peroxisome biogenesis disorder 1Bperoxisome biogenesis disorder 1A (Zellweger)peroxisome biogenesis disorder due to PEX1 defectZellweger spectrum disorders
HGNC:8850UniProt:O43933
SLC5A6Sodium-dependent multivitamin transporterDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Sodium-dependent multivitamin transporter that mediates the electrogenic transport of pantothenate, biotin, lipoate and iodide (PubMed:10329687, PubMed:15561972, PubMed:19211916, PubMed:20980265, PubMed:21570947, PubMed:22015582, PubMed:25809983, PubMed:25971966, PubMed:27904971, PubMed:28052864, PubMed:31754459). Functions as a Na(+)-coupled substrate symporter where the stoichiometry of Na(+):substrate is 2:1, creating an electrochemical Na(+) gradient used as driving force for substrate uptak

LOCALIZAÇÃO

Cell membraneApical cell membrane

VIAS BIOLÓGICAS (3)
Transport of vitamins, nucleosides, and related moleculesBiotin transport and metabolismVitamin B5 (pantothenate) metabolism
MECANISMO DE DOENÇA

Sodium-dependent multivitamin transporter deficiency

An autosomal recessive multisystemic metabolic disorder characterized by early infantile onset, progressive neurodegeneration, global developmental delay, and developmental regression with loss of early motor and cognitive milestones. Additional variable features include seizures, ataxia, spasticity, peripheral neuropathy, immune defects, and osteopenia. Treatment with biotin, pantothenic acid, and lipoate may result in clinical improvement.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
80.0 TPM
Fígado
67.6 TPM
Mama
48.9 TPM
Útero
40.2 TPM
Linfócitos
38.0 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (2)
peripheral motor neuropathy, childhood-onset, biotin-responsiveneurodegeneration, infantile-onset, biotin-responsive
HGNC:HGNC:11041UniProt:Q9Y289
SMPD1Sphingomyelin phosphodiesteraseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Converts sphingomyelin to ceramide (PubMed:12563314, PubMed:1840600, PubMed:18815062, PubMed:25339683, PubMed:25920558, PubMed:27659707, PubMed:33163980). Exists as two enzymatic forms that arise from alternative trafficking of a single protein precursor, one that is targeted to the endolysosomal compartment, whereas the other is released extracellularly (PubMed:20807762, PubMed:21098024, PubMed:9660788). However, in response to various forms of stress, lysosomal exocytosis may represent a major

LOCALIZAÇÃO

LysosomeLipid dropletSecretedSecreted, extracellular space

VIAS BIOLÓGICAS (1)
Glycosphingolipid catabolism
MECANISMO DE DOENÇA

Niemann-Pick disease A

An early-onset lysosomal storage disorder caused by failure to hydrolyze sphingomyelin to ceramide. It results in the accumulation of sphingomyelin and other metabolically related lipids in reticuloendothelial and other cell types throughout the body, leading to cell death. Niemann-Pick disease type A is a primarily neurodegenerative disorder characterized by onset within the first year of life, intellectual disability, digestive disorders, failure to thrive, major hepatosplenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
79.4 TPM
Tireoide
67.2 TPM
Pituitária
65.9 TPM
Aorta
63.0 TPM
Cerebelo
61.4 TPM
OUTRAS DOENÇAS (2)
Niemann-Pick disease type BNiemann-Pick disease type A
HGNC:11120UniProt:P17405
PDXKPyridoxal kinaseDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Catalyzes the phosphorylation of the dietary vitamin B6 vitamers pyridoxal (PL), pyridoxine (PN) and pyridoxamine (PM) to form pyridoxal 5'-phosphate (PLP), pyridoxine 5'-phosphate (PNP) and pyridoxamine 5'-phosphate (PMP), respectively (Probable) (PubMed:10987144, PubMed:17766369, PubMed:19351586, PubMed:31187503, PubMed:9099727). PLP is the active form of vitamin B6, and acts as a cofactor for over 140 different enzymatic reactions

LOCALIZAÇÃO

Cytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Vitamin B6 activation to pyridoxal phosphate
MECANISMO DE DOENÇA

Neuropathy, hereditary motor and sensory, 6C, with optic atrophy

An autosomal recessive neurologic disorder characterized by childhood onset of axonal, sensorimotor polyneuropathy affecting mainly the lower limbs, and adult-onset optic atrophy. Clinical features include progressive distal muscle weakness and atrophy, significant standing and walking difficulties, areflexia, neurogenic pain and progressive visual impairment.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
123.5 TPM
Córtex cerebral
62.5 TPM
Brain Frontal Cortex BA9
58.9 TPM
Brain Anterior cingulate cortex BA24
53.9 TPM
Pituitária
50.0 TPM
OUTRAS DOENÇAS (1)
neuropathy, hereditary motor and sensory, type VIc, with optic atrophy
HGNC:HGNC:8819UniProt:O00764
VWA1von Willebrand factor A domain-containing protein 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Promotes matrix assembly (By similarity). Involved in the organization of skeletal muscles and in the formation of neuromuscular junctions (Probable)

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix, basement membrane

VIAS BIOLÓGICAS (2)
Post-translational protein phosphorylationRegulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
MECANISMO DE DOENÇA

Neuronopathy, hereditary motor, autosomal recessive 7

An autosomal recessive, neuromyopathic disorder that manifests in childhood or adulthood with proximal and distal muscle weakness predominantly of the lower limbs. Affected individuals have difficulty climbing stairs and problems standing on the heels. Most patients have foot deformities, and some may have leg muscle atrophy. Muscle biopsy and electrophysiologic studies are consistent with both a myopathic process and an axonal motor neuropathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
196.9 TPM
Próstata
99.7 TPM
Bladder
93.6 TPM
Esôfago - Muscular
81.6 TPM
Cólon sigmoide
79.6 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (2)
neuronopathy, distal hereditary motor, autosomal recessive 7neuronopathy, distal hereditary motor, autosomal recessive 5
HGNC:30910UniProt:Q6PCB0
SLC5A7High affinity choline transporter 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

High-affinity Na(+)-coupled choline transmembrane symporter (PubMed:11027560, PubMed:11068039, PubMed:12237312, PubMed:12969261, PubMed:17005849, PubMed:23132865, PubMed:23141292, PubMed:27569547). Functions as an electrogenic, voltage-dependent transporter with variable charge/choline stoichiometry (PubMed:17005849). Choline uptake and choline-induced current is also Cl(-)-dependent where Cl(-) is likely a regulatory ion rather than cotransported ion (PubMed:11068039, PubMed:12237312, PubMed:17

LOCALIZAÇÃO

Presynaptic cell membraneCell projection, axonEarly endosome membraneCytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane

VIAS BIOLÓGICAS (2)
SLC-mediated bile acid transportAcetylcholine Neurotransmitter Release Cycle
MECANISMO DE DOENÇA

Neuronopathy, distal hereditary motor, autosomal dominant 7

A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs. HMND7 is characterized by onset in the second decade of progressive distal muscle wasting and weakness affecting the upper and lower limbs and resulting in walking difficulties and hand grip. There is significant muscle atrophy of the hands and lower limbs. The disorder is associated with vocal cord paresis due to involvement of the tenth cranial nerve.

EXPRESSÃO TECIDUAL(Baixa expressão)
Cólon sigmoide
3.2 TPM
Esôfago - Junção
1.8 TPM
Brain Putamen basal ganglia
1.6 TPM
Bladder
1.6 TPM
Esôfago - Muscular
1.5 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (3)
neuronopathy, distal hereditary motor, type 7Acongenital myasthenic syndrome 20distal hereditary motor neuropathy type 7
HGNC:14025UniProt:Q9GZV3
GARS1Glycine--tRNA ligaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the ATP-dependent ligation of glycine to the 3'-end of its cognate tRNA, via the formation of an aminoacyl-adenylate intermediate (Gly-AMP) (PubMed:17544401, PubMed:24898252, PubMed:28675565). Also produces diadenosine tetraphosphate (Ap4A), a universal pleiotropic signaling molecule needed for cell regulation pathways, by direct condensation of 2 ATPs. Thereby, may play a special role in Ap4A homeostasis (PubMed:19710017)

LOCALIZAÇÃO

CytoplasmCell projection, axonSecretedSecreted, extracellular exosomeMitochondrion

VIAS BIOLÓGICAS (1)
Cytosolic tRNA aminoacylation
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2D

A dominant axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.

OUTRAS DOENÇAS (4)
neuronopathy, distal hereditary motor, type 5ACharcot-Marie-Tooth disease type 2Dspinal muscular atrophy, infantile, James typeneuronopathy, distal hereditary motor, type 5
HGNC:4162UniProt:P41250

Medicamentos e terapias

PATISIRAN SODIUMPhase 4

Mecanismo: Transthyretin mRNA RNAi inhibitor

VUTRISIRAN SODIUMPhase 4

Mecanismo: Transthyretin mRNA rnai inhibitor

INOTERSEN SODIUMPhase 4

Mecanismo: Transthyretin mRNA antisense inhibitor

VUTRISIRANPhase 4

Mecanismo: Transthyretin mRNA rnai inhibitor

CHENODIOLPhase 4

Mecanismo: Bile acid receptor FXR agonist

RISDIPLAMPhase 4

Mecanismo: SMN2 pre-mRNA positive modulator

TORIPALIMABPhase 4

Mecanismo: Programmed cell death protein 1 antagonist

ATIDARSAGENE AUTOTEMCELPhase 4

Mecanismo: ARSA exogenous gene

PATISIRANPhase 3

Mecanismo: Transthyretin mRNA RNAi inhibitor

INOTERSENPhase 3

Mecanismo: Transthyretin mRNA antisense inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

1,231 variantes patogênicas registradas no ClinVar.

🧬 FH: NM_000143.4(FH):c.1037G>C (p.Gly346Ala) ()
🧬 FH: NM_000143.4(FH):c.708del (p.Gln237fs) ()
🧬 FH: GRCh38/hg38 1q43-44(chr1:237818970-248924793)x1 ()
🧬 FH: NM_000143.4(FH):c.1462G>T (p.Glu488Ter) ()
🧬 FH: NM_000143.4(FH):c.422G>A (p.Trp141Ter) ()
Ver todas no ClinVar

Vias biológicas (Reactome)

167 vias biológicas associadas aos genes desta condição.

Citric acid cycle (TCA cycle) Mitochondrial protein degradation Regulation of CDH11 Expression and Function Regulation of CDH11 gene transcription Binding of TCF/LEF:CTNNB1 to target gene promoters Aryl hydrocarbon receptor signalling Ribosomal scanning and start codon recognition Translation initiation complex formation Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S GTP hydrolysis and joining of the 60S ribosomal subunit Regulation of NPAS4 gene expression Mechanical load activates signaling by PIEZO1 and integrins in osteocytes Mitochondrial translation termination Respiratory electron transport Complex I biogenesis Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Neddylation Antigen processing: Ubiquitination & Proteasome degradation Cytosolic tRNA aminoacylation Mitochondrial tRNA aminoacylation Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal MHC class II antigen presentation Separation of Sister Chromatids Resolution of Sister Chromatid Cohesion Regulation of PLK1 Activity at G2/M Transition HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Anchoring of the basal body to the plasma membrane RHO GTPases Activate Formins Neutrophil degranulation COPI-mediated anterograde transport COPI-independent Golgi-to-ER retrograde traffic Mitotic Prometaphase AURKA Activation by TPX2 HCMV Early Events Aggrephagy EML4 and NUDC in mitotic spindle formation Interconversion of nucleotide di- and triphosphates TP53 Regulates Metabolic Genes Ubiquinol biosynthesis Class I peroxisomal membrane protein import Selenoamino acid metabolism Transcriptional and post-translational regulation of MITF-M expression and activity Pregnenolone biosynthesis Endogenous sterols Electron transport from NADPH to Ferredoxin Defective CYP11A1 causes AICSR ABC transporters in lipid homeostasis Dengue Virus-Host Interactions EGR2 and SOX10-mediated initiation of Schwann cell myelination PINK1-PRKN Mediated Mitophagy RHOT2 GTPase cycle Factors involved in megakaryocyte development and platelet production Caspase-mediated cleavage of cytoskeletal proteins Sensory processing of sound by outer hair cells of the cochlea Amyloid fiber formation Sphingolipid de novo biosynthesis Unblocking of NMDA receptors, glutamate binding and activation Ras activation upon Ca2+ influx through NMDA receptor RAF/MAP kinase cascade Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation snRNP Assembly SARS-CoV-2 modulates host translation machinery VLDL assembly Chylomicron assembly LDL remodeling Regulation of pyruvate dehydrogenase (PDH) complex Signaling by Retinoic Acid PDH complex synthesizes acetyl-CoA from PYR Lanosterol biosynthesis Protein lipoylation APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway Glutamate and glutamine metabolism Formation of ATP by chemiosmotic coupling Cristae formation Intracellular oxygen transport Mitochondrial unfolded protein response (UPRmt) NADE modulates death signalling Activation of BIM and translocation to mitochondria Activation of caspases through apoptosome-mediated cleavage Export of Viral Ribonucleoproteins from Nucleus NEP/NS2 Interacts with the Cellular Export Machinery Ion homeostasis Ion transport by P-type ATPases Potential therapeutics for SARS Acyl chain remodeling of DAG and TAG Triglyceride biosynthesis MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis Transcriptional regulation of white adipocyte differentiation Activation of anterior HOX genes in hindbrain development during early embryogenesis NGF-stimulated transcription Acyl chain remodeling of CL Beta oxidation of myristoyl-CoA to lauroyl-CoA mitochondrial fatty acid beta-oxidation of unsaturated fatty acids Beta oxidation of palmitoyl-CoA to myristoyl-CoA Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA Beta oxidation of octanoyl-CoA to hexanoyl-CoA Beta oxidation of hexanoyl-CoA to butanoyl-CoA Glyoxylate metabolism and glycine degradation COPI-dependent Golgi-to-ER retrograde traffic Kinesins TRP channels High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells XBP1(S) activates chaperone genes Signaling by ALK fusions and activated point mutants Molecules associated with elastic fibres Defective MMADHC causes MMAHCD Defective MMACHC causes MAHCC Cobalamin (Cbl) metabolism Glycosphingolipid catabolism PLC-gamma1 signalling Signalling to RAS Frs2-mediated activation ARMS-mediated activation Retrograde neurotrophin signalling NGF-independant TRKA activation TRKA activation by NGF Signalling to p38 via RIT and RIN PI3K/AKT activation Signalling to STAT3 COPII-mediated vesicle transport Cargo concentration in the ER Regulation of Complement cascade Glycine degradation Branched-chain amino acid catabolism OGDH complex synthesizes succinyl-CoA from 2-OG OADH complex synthesizes glutaryl-CoA from 2-OA BCKDH synthesizes BCAA-CoA from KIC, KMVA, KIV Loss-of-function mutations in DBT cause MSUD2 Loss-of-function mutations in DLD cause MSUD3/DLDD Branched-chain ketoacid dehydrogenase kinase deficiency H139Hfs13* PPM1K causes a mild variant of MSUD E3 ubiquitin ligases ubiquitinate target proteins Peroxisomal protein import Interaction between L1 and Ankyrins Phase 0 - rapid depolarisation Expression and translocation of olfactory receptors Mitochondrial RNA degradation Mitochondrial mRNA modification Neurofascin interactions Pexophagy Strand-asynchronous mitochondrial DNA replication Scavenging by Class B Receptors Detoxification of Reactive Oxygen Species Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models NFE2L2 regulating anti-oxidant/detoxification enzymes Keratan sulfate degradation CS/DS degradation Hyaluronan degradation Defective HEXA causes GM2G1 (Hyaluronan metabolism) Mitochondrial protein import Biotin transport and metabolism Vitamin B5 (pantothenate) metabolism Transport of vitamins, nucleosides, and related molecules Vitamin B6 activation to pyridoxal phosphate Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) Post-translational protein phosphorylation Acetylcholine Neurotransmitter Release Cycle Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A) Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A) SLC-mediated bile acid transport

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado8
3Fase 33
2Fase 22
·Pré-clínico2
Medicamentos catalogadosEnsaios clínicos· 10 medicamentos · 5 ensaios
✓ Aprovados — podem ser usados hoje
PATISIRAN SODIUMVUTRISIRAN SODIUMINOTERSEN SODIUMVUTRISIRANCHENODIOLRISDIPLAMTORIPALIMABATIDARSAGENE AUTOTEMCEL
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Neuropatia periférica, genética

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

0 ensaios clínicos encontrados.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
7 papers (10 anos)
#1

Development and Validation of a Visual Grading Score of Disease Severity From Gait Videos in Genetic Peripheral Neuropathy.

European journal of neurology2026 Mar

Este estudo desenvolveu e validou o vGASP, uma escala visual que avalia a gravidade de neuropatias periféricas genéticas, como a Doença de Charcot-Marie-Tooth (CMT), a partir de vídeos da marcha dos pacientes. O vGASP mostrou-se rápido, fácil de usar e altamente correlacionado com medidas clínicas validadas. Essa ferramenta oferece uma solução eficaz para o monitoramento remoto de pacientes, superando desafios de acesso a neurologistas e otimizando recursos, o que é crucial para o acompanhamento regular e eficiente de pacientes com essas condições.

🇧🇷 traduzido
#2

Expression of genetic peripheral neuropathies in South African children.

Neuromuscular disorders : NMD2026 Feb

Este estudo sul-africano com 64 crianças com neuropatia periférica genética destaca a dificuldade diagnóstica na região, pois apenas 33% obtiveram um diagnóstico molecular confirmado, com a maioria dependendo de outros métodos. A neuropatia axonal foi a mais comum (73%), e embora a duplicação do PMP22 (CMT1A) tenha sido a causa genética mais identificada entre os casos com diagnóstico molecular, ela parece ser rara em crianças de ascendência africana negra indígena. Isso sublinha a necessidade urgente de melhorar o acesso a testes genéticos e de mais pesquisas para compreender as causas genéticas locais e otimizar os protocolos de diagnóstico para esses pacientes.

🇧🇷 traduzido
#3

Boosting BDNF in muscle rescues impaired axonal transport in a mouse model of DI-CMTC peripheral neuropathy.

Neurobiology of disease2024 Jun 01

Este estudo sobre a neuropatia periférica genética DI-CMTC (um tipo de Charcot-Marie-Tooth) identificou que uma mutação específica compromete o transporte de sinais essenciais ao longo dos nervos. Crucialmente, a pesquisa demonstrou que aumentar os níveis da proteína BDNF nos músculos, seja por injeção ou terapia gênica, corrigiu completamente essa deficiência no transporte axonal. Isso aponta para uma estratégia terapêutica promissora, que foca em impulsionar o BDNF muscular, para pacientes com DI-CMTC e possivelmente outras neuropatias genéticas similares.

🇧🇷 traduzido
#4

Boosting BDNF in muscle rescues impaired axonal transport in a mouse model of DI-CMTC peripheral neuropathy.

bioRxiv : the preprint server for biology2024 Mar 11

Este estudo sobre a neuropatia periférica genética DI-CMTC, causada por mutações na proteína TyrRS, identificou que a forma mutante desta proteína interage de forma anormal com o receptor de BDNF, levando a um transporte axonal deficiente, crucial para a função nervosa. Mais importante, a pesquisa demonstrou que o aumento dos níveis da proteína BDNF nos músculos, seja por injeção direta ou terapia gênica, conseguiu corrigir completamente este transporte axonal prejudicado em modelos murinos. Isso sugere que aumentar o BDNF muscular tem grande potencial como estratégia terapêutica para pacientes com DI-CMTC e outras neuropatias relacionadas.

🇧🇷 traduzido
#5

Simultaneous monitoring of mouse grip strength, force profile, and cumulative force profile distinguishes muscle physiology following surgical, pharmacologic and diet interventions.

Scientific reports2022 Sep 30

Este estudo apresenta um novo aparelho capaz de monitorar de forma detalhada a força de preensão, o perfil de força e a força cumulativa em camundongos, oferecendo uma avaliação mais completa da fisiologia muscular. Para pacientes e médicos, o achado mais relevante é que a neuropatia periférica genética (como a deficiência de lipina 1) exibe um padrão de fraqueza muscular distintamente diferente de outras causas (como lesões nervosas ou efeitos de estatinas), afetando todos os três parâmetros avaliados. Essa capacidade de diferenciar os tipos de comprometimento muscular pode, no futuro, auxiliar em diagnósticos mais precisos e na compreensão de como diferentes doenças afetam a função muscular.

🇧🇷 traduzido

Publicações recentes

Ver todas no PubMed

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Neuropatia periférica, genética.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Neuropatia periférica, genética

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Development and Validation of a Visual Grading Score of Disease Severity From Gait Videos in Genetic Peripheral Neuropathy.
    European journal of neurology· 2026· PMID 41860147mais citado
  2. Expression of genetic peripheral neuropathies in South African children.
    Neuromuscular disorders : NMD· 2026· PMID 41456368mais citado
  3. Boosting BDNF in muscle rescues impaired axonal transport in a mouse model of DI-CMTC peripheral neuropathy.
    Neurobiology of disease· 2024· PMID 38583640mais citado
  4. Boosting BDNF in muscle rescues impaired axonal transport in a mouse model of DI-CMTC peripheral neuropathy.
    bioRxiv : the preprint server for biology· 2024· PMID 38559020mais citado
  5. Simultaneous monitoring of mouse grip strength, force profile, and cumulative force profile distinguishes muscle physiology following surgical, pharmacologic and diet interventions.
    Scientific reports· 2022· PMID 36180720mais citado

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:98497(Orphanet)
  2. MONDO:0020127(MONDO)
  3. GARD:10711(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q55789138(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Neuropatia periférica, genética
Compêndio · Raras BR

Neuropatia periférica, genética

ORPHA:98497 · MONDO:0020127
Prevalência
1-5 / 10 000
Medicamentos
18 registrados
Prevalência
40.0 (Worldwide)
MedGen
UMLS
C5681733
Repurposing
2 candidatos
duloxetinenorepinephrine reuptake inhibitor|serotonin–norepinephrine reuptake inhibitor (SNRI)
levocarnitine-propionatecarnitine palmitoyltransferase inhibitor
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades